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Chapter 1  
Introduction and Significance 
Text partially adapted from: 
Nelson CE, Gupta MK, Adolph EJ, Guelcher SA, Duvall CL. siRNA Delivery from an Injectable 
Scaffold for Wound Therapy.  Advances in Wound Care. 2013; 2(3):93-99 
 
1.1 Motivation 
Impaired wound healing is a significant healthcare problem, and the primary risk group is  
patients with diabetes, a disease that is a prevalent and rapidly growing public health issue in the 
United States and worldwide. Approximately 8% of individuals the US or 23.6 million people have 
diabetes [1]. A global epidemic as well, many developed countries and developing countries alike 
are seeing dramatic increases in the prevalence of diabetes, and these increases threaten to 
reverse economic gains in these countries [2]. Furthermore, the incidence of diabetes has tripled 
from 1980-2006 in the US and the Center for Disease Control predicts that if this trend continues, 
one in three of today’s children will develop diabetes in their lifetime [3].  
 Patients with diabetes are more susceptible to impaired wound healing which results in 
25% of diabetics developing chronic ulcers [4]. For this reason, diabetics suffer increased 
morbidity and mortality having 10 times the rate of lower-limb amputation of non-diabetics [1].  
Morbidity and mortality after lower-limb amputation is high with about one quarter receiving 
additional amputations, and about one third die after one year [5].  
 In addition to the morbidity and mortality associated with chronic wounds, treatment is now 
a $25 billion annual cost to health care and is been described as a “snowballing threat to public 
health”, where the incidence of chronic wounds will grow with the increasing prevalence of 
comorbidities [4]. These statistics highlight the deleterious impact of diabetes in the United States 
today and clearly define a tremendous clinical need for improved therapeutic strategies to reduce 
wound related morbidity and mortality in diabetic patients. 
 
 2 
1.2 Molecular Basis for Non-Healing Wounds 
Diabetes mellitus (type 2) is characterized by insulin resistance and will result in periods of 
sustained hyperglycemia. Currently, diabetes is managed with lifestyle modification followed by 
administration of pharmaceuticals including insulin, metformin, and others which can improve the 
quality of life for these patients. However, in many patients, unmanaged hyperglycemia leads to 
a number of pathologies, notably cardiovascular defects and poor collateral vessel formation [6]. 
As a result, simple skin wounds and pressure ulcers may develop into chronic non-healing 
wounds. Procedures have been developed to improve wound healing and decrease the 
associated morbidity (good wound care). Biologic drugs have recently been sought to correct the 
molecular dysfunction including platelet derived growth factor (PDGF in Regranex®); however, 
50% of wounds still remain unclosed [7].  
Recent evidence points to an impairment in the activation of HIF-1α as a result of prolonged 
hyperglycemia [6] and correcting this abnormality may restore normal wound healing. Prolyl 
hydroxylase domain protein 2 (PHD2) is a negative regulator of HIF-1α [8] and represents a logical 
target for improving HIF-1α activity, stability, and resulting angiogenesis and tissue regeneration 
[9]. This is discussed in more detail in section 2.7.  
As an engineering approach for inhibiting PHD2, small molecule inhibitors, antisense 
oligonucleotides (ODNs), and small interfering RNA (siRNA) have been used. Small molecule 
inhibitors have shown some promise and are a good proof of principle, however, lack specificity 
for PHDs or specific isoforms of PHD and as a result, have undesired non-target effects [10].  
ODNs, and siRNA are much more specific and can be engineered to have a local effect instead 
of a widespread systemic effect. From these antisense approaches, siRNA is the most potent 
capable of 100-1000 times more silencing than ODNs [11]. This motivates the use of PHD2 siRNA 
as a molecular based therapy for treating chronic wounds.  
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1.3 siRNA as a Molecular Therapy for Wound Healing 
Since the discovery of RNA interference in gene regulation, a large volume of research 
has been directed into rapidly developing siRNA for clinical use [12].  siRNA are short (~21-22 
base pairs) double stranded RNA, where the guide strand of the molecule is loaded onto the RNA 
induced silencing complex (RISC), a cohort of proteins intrinsic to mammalian cells. The activated 
RISC identifies the targeted mRNA through complementary base pairing and cleaves the mRNA.  
The guide strand and activated RISC are conserved and may reinitiate degradation of additional 
mRNA molecules [13], making the process catalytic and thus more potent than stoichiometric (i.e. 
protein or small molecule) inhibitors.  These favorable properties of siRNA have led to rapid 
advancement into clinical tests for a variety of conditions including respiratory syncytial virus 
infection, macular degeneration, hepatitis B, renal failure, macular oedema, pachyonychia 
congenital, and solid tumors [14-16]. 
siRNA is regarded to have untapped clinical potential, but one of the major challenges to 
harnessing RNA interference pharmaceutically is efficient cytoplasmic delivery of the siRNA 
biomacromolecules into target cells. “Naked” siRNA has a very short half-life in vivo due to rapid 
degradation by nucleases and clearance through kidney filtration.  siRNA is also relatively large 
in molecular weight, anionic, and polar, making it impermeable to cell membranes.  This is 
problematic for initial cellular internalization and for escape from endo-lysosomal vesicles 
following uptake by endocytosis.  Thus, siRNA carriers are required to package and protect the 
siRNA and deliver siRNA into the cytoplasm of the cell where the RISC machinery is located. 
Polycations have been heavily studied as an approach to package and protect siRNA and enable 
endosome escape via the proton sponge effect. However, most polycations are characterized by 
cytotoxicity and instability in vivo, and recent efforts have aimed to overcome these limitations. 
Although siRNA activity is catalytic, it does have a finite half-life in the cell.  Previous 
reports generally note maximum silencing at around two days post-transfection [17] with normal 
gene expression  restored by approximately one week in rapidly dividing cells [18].   One approach 
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to extend silencing may be to achieve sustained, local release from scaffolds injected or 
transplanted onto the wound.  Mostly natural materials such as alginate, collagen, and agarose 
have been pursued for biomaterial-based siRNA delivery to this point [19-22].  Recently, key 
proof-of-concept studies were published describing effective topical siRNA gene silencing in vivo 
using agarose scaffolds loaded with siRNA packaged into the commercial reagent Lipofectamine 
2000.  This particular approach represents a significant breakthrough, though it did suffer from 
the potential limitation of siRNA diffusing from the scaffold in a relatively rapid “burst” release that 
required removal and re-application of siRNA-loaded scaffolds to achieve better and more 
sustained siRNA activity [21, 22].  It may be possible to achieve more optimal wound therapies 
with delivery systems that integrate efficient, nontoxic siRNA carriers into an injectable delivery 
matrix that can achieve sustained and tunable rates of siRNA release for greater than 1 week.   
 
1.4 Approach 
Our work has focused on the combination of two complementary biomaterials that enable 
efficient, sustained siRNA intracellular delivery to skin wounds (Fig. 1.1).The first class is a pH-
responsive micelle, referred to here as the smart polymer nanoparticle (NP).  The NP is capable 
of electrostatic loading and nuclease protection of siRNA in addition to pH-dependent membrane 
disruptive activity that can mediate escape from endo-lysosomal vesicles. This NP is self-
assembled from a reversible addition fragmentation chain transfer (RAFT) synthesized diblock 
copolymer recently described [23]. This diblock polymer (see structure in Fig. 1.1A) is composed 
of siRNA condensing block consisting of 2-dimethylaminoethyl methacrylate (DMAEMA).  This 
block is the relatively hydrophilic block and forms the corona of the micelle.  It has pendant tertiary 
amines that are approximately 50% protonated at physiologic pH, which enables electrostatic 
loading of siRNA into the “shell” of the si-NP (Fig. 1.1B).  The second block is a more hydrophobic 
and approximately charge neutral terpolymer block.  This terpolymer contains approximately 
equimolar quantities of 2-propyl acrylic acid (PAA) and DMAEMA in order to maintain charge 
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neutrality at physiologic pH.  Butyl methacrylate (BMA) is the third monomer and is incorporated 
to increase the hydrophobic character and drive micelle self-assembly in aqueous solution.  
Importantly, both the PAA and DMAEMA monomers are pH-responsive (i.e. environmental pH 
dictates their protonation state and affects their physical properties), and it is this characteristic 
that mediates escape from endo-lysosomes upon acidification of these vesicles following cellular 
internalization of the carrier (Fig. 1.1D).  
 
Figure 1.1 – Schematic illustrating the approach used in this study. A) RAFT-synthesized diblock co-
polymer with the siRNA condensing block shown in blue and the pH responsive block in red B) In aqueous 
solutions, the diblock copolymer self-assembles into micellar nanoparticles with a positive surface charge 
that can be used to electrostatically condense siRNA. C) Lyophilized si-NPs are mixed into the polyol 
component and then added to the LTI and water to form a porous PUR scaffold containing embedded si-
NPs. D) The si-NPs can diffuse out of the PUR scaffold, and, upon release, si-NPs can be internalized and 
efficiently delivered in a bioactive form into the cytoplasm of cells. 
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The second biomaterial is an injectable polyurethane (PUR) scaffold composed of a polyol 
component that is 60% poly(ε-caprolactone), 30% poly(glycolide), and 10% poly(D,L-lactide), and 
a hardening component, lysine triisocyanate (LTI).  The polyol and the LTI react to form urethane 
bonds, and water is added to the reaction to produce CO2 that creates scaffold porosity (Figure 
1C).  PUR-based scaffolds are desirable because components can be mixed and injected into a 
wound site where it quickly cures in situ, thus enhancing its flexibility and potential for clinical use.  
Also, the PUR adheres to underlying tissue, does not elicit significant inflammation [24], and 
biodegrades at tunable rates into biocompatible products [25]. Furthermore, the scaffold 
morphology is highly porous, which allows for ingrowth of granulation tissue and promotes tissue 
remodeling. The PURs have been previously used for controlled delivery of growth factors but 
have not been previously employed for release of carriers for intracellular-acting biologic drugs. 
 
1.5 Innovation 
Currently, there are no commonly utilized clinical applications of intracellular-acting biomacro-
molecular drugs (growth factors act on extracellular receptors).  The delivery requirements for 
intracellular-acting biomolecules like siRNA are more rigorous because they cannot cross cellular 
membranes, and when endocytosed, the predominant fate is enzymatic degradation in lysosomes 
or recycling and extracellular clearance. Here, we describe a “smart” polymer carrier that 
“recognizes” environmental changes to become membrane disruptive in the lower pH 
environment of endosomes.  This innovative approach to gene inhibition may enable a new level 
of pharmaceutical breadth and specificity that would overcome many of the shortcomings of small 
molecule drugs and also allow manipulation of intracellular targets that were previously 
considered “undruggable”.  The majority of recent applications of siRNA have focused on in vitro 
validation, systemic in vivo delivery, or in vivo applications where siRNA formulations have been 
injected locally in saline with no regard for persistence of sustained bioactivity (i.e. intraocular or 
intratumoral injection, lung inhalation). The use of siRNA for regenerative applications could be 
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tremendously enhanced by means of sustained, local delivery from scaffolds that serve as porous 
tissue templates.  The innovative combination of si-NPs and PUR scaffolds provides a porous 
scaffold template for cell in-growth, ease of delivery for clinical applications (injectability), multiple 
levels of tunability for release kinetics, and ultimately, the ability to optimize siRNA activity for 
specific target genes and pathological applications. Finally, targeting PHD2 to increase 
angiogenesis and improve wound healing in tissue regenerative scaffolds is a novel and 
potentially a highly rewarding pursuit.  
 
1.6 Specific Aims 
The central hypothesis of this study is that efficient and temporally controlled administration of 
siRNA can be used to improve tissue regeneration, specifically through targeting PHD2.   This 
hypothesis will be evaluated through the completion of the following four specific aims:  
Specific Aim 1: Synthesize and characterize a novel siRNA delivery platform in 
vitro: PUR based delivery of endosomolytic NPs carrying siRNA will be validated in vitro 
for controlled release and knockdown efficiency.  
Specific Aim 2: Asses the in vivo activity and biocompatibility of the siRNA delivery 
platform: The delivery platform will be validated in vivo using subcutaneous implants in 
mice.  Dicer substrate siRNA against model genes luciferase and cyclophilin B (PPIB) will 
be used to optimize and validate the delivery system in vivo.  The result of this aim will be 
a thoroughly validated tissue-engineering scaffold based siRNA delivery platform with 
precise temporal control for gene silencing in vivo.  
Specific Aim 3: Improve in vivo angiogenesis through the delivery of siRNA against 
PHD2: Validated dicer substrate siRNA against PHD2 will be delivered using the validated 
platform developed in Specific Aim 2. Therapeutic response in subcutaneous implants will 
be evaluated by monitoring gene expression with qRT-PCR. Blood vessel growth will be 
evaluated post-mortem with microCT and immunohistochemistry.  
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Specific Aim 4: Investigate sustained PHD2 knockdown for improved wound 
healing in diabetic rats: The therapeutic effect of PHD2 silencing will be tested with 
polyester urethanes implanted in excisional wounds in streptozotocin (STZ) induced 
diabetic rats.  Gene expression will be monitored by qRT-PCR and blood vessel growth 
will be evaluated by histology. 
 
1.7 Outline 
 Herein, a thorough description of the development of a powerful platform for temporally 
controlled local gene silencing is given. Chapter 2 will provide a concise and targeted review of 
the previous work in local RNA delivery. Chapter 3 will detail the initial development of the platform 
and in vitro confirmation of bioactivity and biocompatibility. Chapter 4 will describe the in vivo 
testing of the platform and application of the platform for PHD2 gene silencing. In Chapter 5, an 
additional application of siRNA will be considered utilizing endosomolytic NPs for intravenous 
gene silencing. Finally, a summary with regard to broader impacts, challenges, and continuing 
work will conclude this writing. Each of the research chapters (3-5) will contain a concise 
introduction and methods with their own discussion and conclusions. 
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Chapter 2 
Background: Local RNAi for Regenerative Medicine 
Text partially adapted from:  
Li HM*, Nelson CE*, Evans BC*, Duvall CL.  "Delivery of Intracellular-acting Biologics in Pro-
Apoptotic Therapies".  For a special issue entitled "Development of drugs interfering with 
apoptosis" in the journal Current Pharmaceutical Design. 2011; 17(3): 293-319. *Equally 
Contributing 1st authors. 
 
Nelson CE, Gupta MK, Adolph EJ, Guelcher SA, Duvall CL. siRNA Delivery from an Injectable 
Scaffold for Wound Therapy.  Advances in Wound Care. 2013; 2(3):93-99 
 
Nelson CE, Gulecher SA, Duvall CL. Local RNAi for Regenerative Medicine. In preparation. 
  
 
2.1 Introduction 
Since the discovery of RNA interference (RNAi) 16 years ago, researchers have rushed 
to develop therapeutics to treat a broad range of conditions by powerfully and specifically down 
regulating target genes. Regenerative medicine is among the diverse fields of research that RNAi 
may benefit by allowing precise control over genes that prohibit tissue regeneration. The clinical 
potential of successful strategies includes chronic wound healing, critical bone defect formation, 
organ/tissue replacement, and others. The primary barrier for utilizing RNAi for any application is 
the extraordinary delivery barriers that prevent RNAi therapies from reaching the target location 
(i.e. the cytoplasm of target cells). In addition to the delivery barriers of intravenous RNAi 
applications, additional considerations should be taken for regenerative medicine including local 
delivery, sustaining the delivery to target tissues, providing biocompatible and tissue inductive 
materials for regrowth, and controlling spatial and temporal availability of small interfering RNA 
(siRNA).  
This review is focused on the material development for local administration of therapeutic 
siRNA for regenerative medicine. The review will begin with a description of siRNA and its 
mechanism. Strategies for siRNA modification, intracellular delivery, and sustained local delivery 
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will be described with discussion on advantages and disadvantages of the systems. Finally, gene 
targets of interest will be discussed for improving regenerative medicine.  
A rapidly growing area of research, RNAi has several very thorough recent reviews on 
topics related to this review. The reader is referred elsewhere on the following subjects: other 
antisense strategies in regenerative medicine [26], molecular modifications  [27], detailed reviews 
on materials for intracellular delivery [27, 28], targeted delivery [29], siRNA-conjugate systems 
[30], physical methods for local/topical delivery [31], and finally, a most recent clinical update [28]. 
 
2.2 SIRNA Discovery and Mechanism 
Controlled manipulation of gene expression using RNAi has been rigorously pursued for 
almost two decades now, and thorough elucidation of this mechanism combined with recent 
breakthroughs in RNA delivery technologies have RNAi poised to make a tremendous clinical 
impact. RNAi is an especially promising therapeutic approach for inhibition of genes related to 
tissue regeneration (inflammation, cell cycle control, etc), or other relevant targets because it 
allows for optimal therapeutic specificity and breadth (i.e., in theory, any desired gene target can 
be efficiently silenced). The initial discovery of RNAi came in 1990 when Napoli et al. observed 
an unexpected reduction in expression when delivering RNA in an attempt to overexpress 
chalcone synthase in Petunias [32]. Others elucidated and applied this finding by delivering 
antisense oligodeoxynucleotides (ODN), complementary sequences of DNA, which yielded 
modest reduction in gene expression in C. elegans [33]. In 1998, Fire et al. showed that 
intracellular-acting double stranded RNA (dsRNA) was more effective than either the sense or 
anti-sense strand alone [12]. In fact, dsRNA has been shown to be 100 to 1000 times more 
effective than ODNs due to a longer half-life and greater potency [11]. Over the next few years, 
researchers proved that endogenous RNAi, known as microRNA (miRNA), exists and that it 
serves as a natural, post-transcriptional controller of gene expression where cellular machinery 
selectively degrades complementary mRNA in an enzymatic manner [13]. The elucidation of 
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similar machinery for RNAi in mammalian cells further heightened the interest in therapeutically 
harnessing these pathways [34]. 
Since these early findings, the mechanisms of ODN and that of miRNA, dsRNA, siRNA, 
and short hairpin RNA (shRNA) have been more clearly elucidated (Fig. 2.1). Single-stranded 
antisense ODN are thought to function by multiple mechanisms including translational arrest due 
to steric blockage of ribosomes by ODN-mRNA Watson-Crick base pairing and also through 
RNase-H-mediated cleavage of both the ODN and mRNA strands [35]. Endogenous RNAi 
molecules in the form of miRNA enter the cytoplasm after transcription, or alternatively, 
functionally-similar dsRNA can be exogenously delivered. shRNA that more closely mimic the 
structure of endogenous miRNA have also been exogenously delivered [36]. In each of these 
cases, the RNase III family enzyme Dicer cleaves the miRNA/dsRNA/shRNA to produce guide 
RNA, more commonly known as siRNA. siRNA are double-stranded RNA 19-21 base pairs in 
length with 3’ nucleotide overhangs [37], these molecules can assemble into the RNA induced 
silencing complex (RISC), a nuclease complex that degrades complementary mRNA in a 
sequence specific, enzymatic manner [13]. Traditional siRNAs have been 19-21 nucleotides that 
bypass the initial dicer processing and are loaded into the RISC.  Recent work has suggested 
that dsRNAs that contain a 27mer antisense strand and a 25mer sense strand may have an 
increased potency of 10X or more when compared with their 21mer siRNA counterparts [38].  This 
“dicer substrate siRNA” (DsiRNA) is now being used as a more potent siRNA to lower the required 
dose which minimizes dose-dependent off target effects. Further, siRNA prediction tools are 
improving through the use of predicative algorithms and automated neural networks [27].  
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Figure 2.1. Mechanisms of RNA interference (A) ODN silencing is believed to be induced by stericly 
blocking translation through hybridization with mRNA and RNAse-H mediated degradation of both the ODN 
and mRNA (B) Proposed mechanisms for RNA interference by miRNA, shRNA, dsRNA, and siRNA. 
Endogenous miRNA, which is made transcriptionally, and exogenously delivered shRNA/dsRNA must all 
be first processed into siRNA, double stranded RNA molecules around 20 base pairs in size. siRNA is 
loaded onto the RISC complex and mediates degradation of mRNA complementary to the antisense siRNA 
strand. For each type of therapeutic RNAi, the exogenous RNA must reach the cytoplasm to interact with 
mRNA and other intracellular machinery required for gene silencing.  
 
Because of the tremendous promise of siRNA to be used therapeutically (i.e., for silencing 
pro-inflammatory genes in wound healing), RNAi has been pursued rigorously in many 
applications. The main issue with using RNAi clinically is with the delivery barriers that must be 
addressed between the initial application of siRNA (either intravenously or topically) and the target 
RISC machinery.  
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2.3 Barriers 
Based on the mechanism of siRNA in Fig. 2.1, cytoplasmic delivery is required for RNAi 
to occur. In order to achieve cytoplasmic delivery, an array of barriers must be navigated that 
depends on the delivery route and the target tissue of interest. As a result, clinical translation of 
siRNA rests in solving the delivery barriers.  
 
Delivery Barriers for Systemic Administration 
Systemic administration of siRNA presents several significant delivery barriers that must 
be addressed for clinical translation. These barriers are summarized in Fig 2.2. (1) siRNA is 
rapidly degraded in the in vivo environment by nucleases [39],  and carriers may be opsonized or 
cleared from the circulation [40, 41]. (2) siRNA or carriers must exit the vasculature at the target 
tissue either by the EPR in tumors or through some active targeting mechanism. (3) siRNA or 
carriers must provide some active uptake mechanism to facilitate uptake as siRNA does not 
readily diffuse across cellular membranes. (4) In many cases, siRNA or carriers are taken into 
endosomes leading to lysosomes for degradation or exocytosed (5) If endocytosed, siRNA or 
carriers must provide some endosome escape mechanism to reach the cytoplasm. (6) Finally, 
siRNA must be released from the carrier in the cytoplasm to begin RNAi [42-45]. Stability of 
biologics is a primary concern considering the harsh environment encountered in vivo.  
 
Delivery Barriers for Local Administration and Regenerative Medicine 
By delivering siRNA with local drug delivery depots, some of the drug delivery barriers of 
systemic application are avoided including stabilization for the intravenous environment and 
tissue targeting. However, in some local delivery applications, the skin or other tissues may 
present an additional barrier to delivery and must be addressed. The delivery barriers associated 
with topical delivery are discussed in detail by elsewhere [31] with regards to delivery to the skin, 
lung, eye, nervous system, digestive system, and vagina. For regenerative medicine applications, 
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the target cells are ideally in direct contact with the material. For example, in wound healing 
applications the skin barrier is absent and infiltrating cells are the main target.  
 
Figure 2.2. Intracellular delivery barriers. 1) Upon entering systemic circulation, the drug formulation 
must protect the biomacromolecule from enzymatic degradation and serum protein destabilization and/or 
opsonization. 2) Drug circulation half-life needs to be long enough such that the drug persists in the 
vasculature until it accumulates (through specific targeting or nonspecifically thorough the enhanced 
permeation and retention effect) in the target tissue. 3) The drug must interact with the cell membrane to 
initiate internalization, which can result in uptake into an endosomal (or pinocytic) vesicle. 4) If no 
endosomal escape mechanism is present, the drug can be degraded in the lysosome, remain in the late 
endosome, or undergo trafficking for exocytosis. 5) If the drug is able to escape the endo-lysosomal 
pathway, it is released where it can diffuse to molecular targets in the cytoplasm. 6) If attached to a carrier 
or loaded within a nanoparticle such as a liposome, polyplex, etc., the drug may need to be released from 
this formulation to become bioavailable. 
 
Another consideration for local administration of siRNA is to create a drug delivery depot 
for sustained release. Though the enzymatic action of siRNA generates potent gene silencing, 
the activity has a finite half-life.  In rapidly dividing cells (e.g. a healing wound), a maximum 
silencing effect is noted near two days post-transfection [17] with gene silencing nearly absent in 
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one week [18]. It may be beneficial to create platforms with tunable release profiles in order to 
allow gene silencing platforms to be tailored to specific pathological applications.  
Finally, local drug delivery depots must be biocompatible, non-toxic, and have well-
characterized degradation and clearance mechanisms. To serve in a regenerative medicine 
capacity, it may also be beneficial for the platform to serve as a tissue template for de novo tissue 
formation [46]. A careful balance of the above considerations may create the idealized platform 
for regenerative medicine.  
 
2.4 siRNA biochemistry 
A major effort in adapting siRNA for therapeutic use is the advanced chemistry and 
modifications to create more stable siRNAs, bioconjugates of siRNA, or novel nucleic acid 
nanoparticles. This body of work may result in siRNAs that are more stable in vivo, provide 
intrinsic cellular uptake, and in some cases, may provide a means for using no additional carrier. 
Some of the most recent and notable examples are outlined below. 
 
siRNA Design 
Many of the characteristics of idealized siRNA sequences were initially identified by 
Elbashir and authors. For example they discovered that duplexes made of 21 base pairs with 3’ 
overhangs two nucleotides in length are optimal, and they also determined that mismatches 
between the antisense siRNA and mRNA in the middle of the siRNA can abolish activity, while 
the 3’ nucleotide has little effect on gene silencing [34, 47, 48]. Later work would identify that 
double stranded RNAs with a 25-mer sense and 27-mer antisense to be more ideal for gene 
silencing [27]. Reynolds and co-authors more recently completed a systematic, mass screening 
of siRNA sequences for two genes and identified low guanine/cytidine content, a low internal 
stability at the 3’ end of the sense strand, and lack of inverted repeats as desirable siRNA 
characteristics in addition to uncovering sense strand base preferences at specific sites in the 
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sequence [49]. siRNA sequence optimization is a rapidly changing field and is covered in detail 
elsewhere [50, 51]. One common approach to silencing a new gene is to acquire several siRNA 
sequences that satisfy these design criteria and that target different loci on the mRNA. The 
sequences can be either pooled together or screened individually to identify an optimal sequence 
for further study. Off-target gene silencing and nonspecific immune responses mediated through 
toll-like receptors (TLRs) can also be triggered by suboptimal siRNA sequences, and instances 
have occurred where nonspecific effects have been misinterpreted as siRNA-driven phenotype 
modification resulting from silencing of a target gene [52]. However, siRNA therapeutic potential 
remains strong as chemical modifications and new rules for sequence identification are 
progressing in-step with the iterative improvements in delivery approaches. In preclinical studies, 
testing for immune activation and verifying phenotypes independently using different siRNA 
sequences against the gene of interest are desirable standards of practice [53].  
 
Chemical Modifications 
A major hurdle for the use of siRNA in vivo is the threat of nuclease degradation.  siRNA 
carriers may protect siRNA from nucleases but for unprotected siRNA, modification patterns have 
been used to improve stability. The modifications are usually on the 2’ position including 2’-O-
methyl (2OME), 2’deoxy-2’-floro, 2’-O-(2-methoxyethyl), 2’-deoxoy-2’-floro-β-D-arabinonucleotide 
(FANA), and a methylene bridge connecting the 2’-O with the 4’-C (locked nucleic acid) [30]. One 
of the most common modifications is a 2’-O-Methyl modification, which is a naturally occurring 
nucleotide [27] that improves duplex stability (Tm) and nuclease resistance without hindering 
activity, causing toxicity, or being immunostimulatory [54].  
As mentioned above, one potential concern is that the intracellular delivery of exogenous 
dsRNAs or siRNAs may lead to the recognition by TLRs.  TLRs recognize the molecular pattern 
of dsRNA and respond as a defense mechanism toward a viral genome.  This effect could result 
in pathological inflammation in clinical trials and has also led to the misinterpretation of pre-clinical 
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studies related to viral repression, oncology, angiogenesis, and inflammation [55]. TLRs 
recognition is thought to be sequence dependent [56] and carefully selected siRNA sequences 
may avoid recognition by TLRs. Further, chemical modification on the backbone of the dsRNA 
may eliminate TLR activation while having negligible effects on the potency of gene silencing [55].  
In fact, only minimal modifications of 2-OMe are required to avoid an immune response [57].   
 
Nucleic Acid Based Carriers 
 Several groups are working to harness genetics to create siRNA carriers entirely from 
nucleic acids. Interesting work is being done in creating self-assembled oligonucleotide-
nanoparticles that are comprised entirely of DNA and siRNA that can be modified to present a 
targeting ligand on the surface [58]. Self-assembling microsponges comprised entirely of hairpin 
RNA have been created that carry more than 500,000 copies of siRNA per microsponge [59]. 
Also, RNA based aptamers conjugated to siRNA have demonstrated effectiveness in vivo 
suppressing HIV-1 [60]. 
 
Conjugates 
 Combined with the work to stabilize siRNA in vivo through chemical modifications, another 
approach to improve uptake of siRNA is to conjugate various biomolecules directly to the nucleic 
acid. These molecules include polymers, peptides, lipids, antibodies, and aptamers. Conjugate 
based siRNA delivery approaches have been reviewed extensively elsewhere [28, 30]. Notably, 
Cholesterol and α-tocopherol has demonstrated improved stability against nuclease degradation 
and increased cellular internalization [61-64]. Peptides have also been used to increase cell 
delivery. Some successful approaches using peptides is to conjugate siRNA with the RGD motif 
from integrin-binding peptides which has lowered the dose required for gene silencing [65]. Also, 
palmatic acid conjugated dicer substrate siRNAs have been shown to have enhanced effect in 
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gene silencing [66]. Conjugates may represent an exciting new approach for scaffold based 
delivery (section 2.6).  
 
2.5 Intracellular Delivery Strategies 
Another strategy for improving pharmacokinetics and cellular bioavailability of siRNA is to 
incorporate a carrier. Typically these carriers contain cationic moieties that allow electrostatic 
complexation of siRNA. These carriers may take many forms including nanoparticles, liposomes, 
lipids, and polymers. Intracellular delivery vectors have been reviewed extensively [27, 28, 67] 
but for the sake of this review, they are discussed in detail. For local delivery strategies (section 
2.6) it is important to consider the compatibility of the intracellular delivery vehicle with the local 
delivery depot.  
 
Physical Methods: Electroporation, Iontophoresis, Sonophoresis, Photochemical Internalization 
and Laser Irradiation  
There are a variety of physical methods used for in vitro transfection or in some cases in 
vivo application to superficial pathologies but are generally considered to be too invasive for most 
therapies. These include electroporation, iontophoresis, sonophoresis, photochemical 
internalization and laser irradiation. Electroporation is a technique where high voltage pulses are 
applied to a tissue (or cell culture) triggering a voltage drop stimulating nano-pores in the cell 
membrane which allows larger molecules to diffuse across [68-71]. Iontophoresis utilizes the 
application of a constant current to move charge molecules (e.g. siRNA) through a tissue, typically 
the epidermis [72, 73]. This technique has been used for siRNA for ocular gene therapy [74]. 
Sonophoresis uses ultrasound to disrupt lipid structure in various tissues primarily for transdermal 
drug delivery [75]. Iontophoresis and sonophoresis do not always necessitate cellular 
internalization however, and may be limited in the uptake of siRNA. This leaves electroporation, 
which may negatively affect cell viability [76, 77].  
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Using photochemical internalization has also been explored where photosensitizing 
agents exposed to a light source generate singlet oxygen species that permeabilize membranes 
[78]. Photochemical internalization has been used to prolong siRNA-mediated gene silencing [79]. 
As a therapy, however, photochemical internalization is limited by the availability of the light 
source and possible toxicity. Laser irradiation is another technique that involves using a high-
powered laser thought to disrupt intracellular connections allowing increased drug permeation 
[80]. This technique has been used to increase siRNA delivery transdermally [81]. Laser 
irradiation may improve siRNA transport through skin, but may still not overcome intracellular 
delivery barriers.  
 
Cell-Penetrating and Fusogenic Peptides  
Cell-Penetrating Peptides and fusogenic petides have been developed that mimic viral 
domains that allow intracellular localization of their genetic material. CPPs have been developed 
based on naturally occurring sequences (e.g. TAT of HIV-1) or synthetic sequences (e.g. 
Arginine-rich sequences) [70, 82-88]. Cell entry mechanisms are hypothesized to include 
membrane fusion via binding of CPPs to cell surface proteoglycans, the endocytosis pathway 
(caveolin-dependent, clathrin-dependent, or caveolin- and clathrin-dependent), and 
macropinocytosis [89-92]. An exhaustive list is given in Table 1 of the following review [67]. Many 
CPPs contain cationic peptides (poly(arginine)) which make these CPPs logical electrostatic 
complexing agents for siRNA.  
Fusogenic peptides may overcome an additional intracellular barrier within the endo-
lysosomal pathway. Peptides with fusogenic activity have an amphipathic structure but transition 
to lipophilic at lower pH environments characteristic of endosomes and lysosomes allowing 
membrane disruption. An exhaustive list is given in Table 2 in the following review [67]. One of 
the most widely utilized fusogenic peptides is the N-terminal sequence of the Influenza 
hemagglutinin subunit HA-2 and its derivatives [93-96]. 
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It is important to consider that some CPPs have been shown to have cytotoxic effects 
depending on the synthetic route and CPP formulation used (e.g. some retroinverso cell 
penetrating peptides have been shown to result in severe cytotoxicity mediated through non-
specific side effects) [97]. Other potential disadvantages of CPPs include poor serum and 
protease stability and their indiscriminate cell entry, which could be problematic for systemic 
delivery applications where specific cells are targeted. 
 
Viral Transfection 
Viral transfection may be a powerful means for incorporating DNA into cells in vitro or 
target tissues in vivo. DNA sequences can be engineered to generate expression for a missing 
or underexpressed gene or alternatively to code for a shRNA that is cleaved by dicer to an siRNA. 
Viral based gene therapy has been used extensively in research, however strong concerns have 
been raised about using viral transfection in human clinical trials [98]. Viral transfection is reviewed 
extensively elsewhere [99] and is considered out of the scope of this review  
 
Lipids/Liposomes 
One of the most common methods for nucleic acid transfection is formulation with lipids 
[100-102]. Lipid agents can form vesicles with a lipid bilayer membrane surrounding an aqueous 
interior where hydrophilic drugs can be encapsulated, or cationic lipids can be used to form 
lipoplexes with anionic nucleic acids. Lipids can either fuse to the cell membrane or enter the cell 
by endocytosis, eventually releasing their cargo into the cytoplasm [56, 103]. Information on 
liposome preparation, physicochemical properties, and applications can be found in more detail 
in a review of liposomal drug delivery systems by Samad et al. [103]. Lipids are commonly 
combined with other components to incorporate added functionality. For example, Morrissey et al 
used a cationic and fusogenic lipid (SNALP) delivery vesicle coated with a PEG-lipid layer to 
provide a neutral, hydrophilic exterior [104].   
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Polymers and Nanoparticles 
One of the simplest ways to transfect cells with nucleic acid in vitro is with the electrostatic 
complexation with a linear cationic polymer which is best represented by linear polyethyleneimine 
(PEI). Cationic polymers are a logical approach for siRNA delivery because they electrostatically 
condense siRNA, protect from nuclease degradation, are attracted to the anionic cell membrane, 
and provide a mechanism for endosome escape through the proton sponge effect [105-109]. 
Examples include poly(L-lysine), linear and branched poly(ethylenimine) (PEI), poly(amidoamine) 
(PAMAM) dendrimers, poly(β-amino esters) (PBAE), and histidine and/or imidazole containing 
copolymers [110-116]. In addition, several natural polymers have been used to transfect siRNA 
including atelocollagen [117, 118] and chitosan [119]. Finally, several groups have combined 
cationic polymers with inorganic nanoparticles that provide dual functions including additional 
therapeutic functionalities or diagnostic capabilities. Noteworthy examples including gold 
nanoparticles (AuNPs) coated with cationic polymers [120] and quantum dot nanoparticles [121, 
122].   
Careful consideration into the use of cationic polymers in vivo must be taken. Cationic 
complexes also induce cellular toxicity at high concentrations, indiscriminately targets cell types, 
and may be unstable when exposed with competing ions in vivo particularly when exposed to the 
glomerular basement membrane in kidneys [123, 124]. Another concern is an irreducible 
complexation of polymer with siRNA in the cell cytoplasm preventing RISC uptake. Some 
approaches toward this problem have been to use a bioreducible disulfide linkage to connect 
siRNA to the polymeric carrier instead of electrostatic complexation [125, 126]. Another approach 
has been the use of hydrolytically degradable cationic moieties that results in a charge reversal 
of the polymer from a tertiary amine to an acrylic acid [127]. 
Polymer biodegradability can also be a significant advantage as exemplified by PBAE 
carriers, which decompose into cytocompatible, low molecular weight degradation products and 
are significantly less toxic than PEI and poly(L-lysine) [128, 129].  
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Stimuli-sensitive Polymers 
Synthetic polymers can be used to mimic the activity of fusogenic peptides by responding 
to the low pH intracellular trafficking compartments to prevent lysosomal degradation or exocytotic 
recycling. These polymers are designed to be inert and membrane compatible at physiologic pH, 
but membrane disruptive at low pH. The primary class of polymers is represented by anionic 
acrylic acids including poly(ethylacrylic acid) and poly(propyl acrylic acid). These polymers 
become more hydrophobic in acidic environments, triggering adoption of a less solvated, compact 
globule conformation that partitions into and disrupts lipid bilayers [105, 107, 130, 131]. Polymers 
and copolymers of PPAA have been explored for siRNA delivery [132, 133]. 
Murthy et al. developed a related class of “encrypted” polymers that also have lipophilic 
activity that disrupts endo-lysosomal membranes. In the encrypted delivery system, PEG 
polymers attached via acid-labile acetal linkages “shield” a hydrophobic, endosomolytic polymer 
backbone until being shed upon exposure to acidic pH [134, 135]. 
 
PEGylation and Targeting 
 For intravenous applications, cationic shell materials have several major drawbacks. 
Cationic materials cause erythrocyte aggregation, opsonization, preferential distribution to the 
lungs, and possibly pulmonary emboli and mortality [136-139]. Modification with poly(ethylene 
glycol) (PEGylation) is the primary method used in improving pharmokinetics and minimize non-
specific uptake and toxicity [140-145]. PEGylation has been used to improve the delivery of PEI, 
poly-L-lysine, PAMAM, PPI dendrimers, PDMAEMA, and BMA-DMAEMA complexes [124, 146-
150]. Careful balance must be achieved because PEGylation can also reduce therapeutic efficacy 
by interfering with cellular uptake and endosomal escape [143]. One way to mitigate this loss in 
activity is to incorporate a mechanism for “shedability” or to have a PEG protecting layer be 
cleaved off by specific enzymes in the target tissue [151, 152]. 
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In addition, cationic materials typically target cell membranes non-specifically and may 
require a targeting scheme to ensure desired biodistribution. PEGylated carriers have sacrificed 
cell uptake to improve biocompatibility and may require targeting molecules to improve uptake in 
the target tissue. Many of the targeting molecules created for this purpose are geared toward 
cancer applications with targeting molecules bombesin, the peptide EPPT, anisamide, folic acid, 
and transferrin representing only a small sampling of the available targeting molecules [145, 153-
157].  
For local delivery applications, PEGylation and tissue targeting may not be required as 
nanoparticles with condensed siRNA released from a local depot tend to have a primary effect in 
the local tissue without widespread effects [158].  
 
2.6 Local Delivery Strategies 
Local delivery of biologics has been pursued for tissue engineering and regenerative 
medicine with the goal to improve tissue regeneration by directing cellular responses. 
Biomacromolecules including growth factors [159] and plasmid DNA [160] have been delivered 
from tissue engineering matrices. Recently, several groups (including our own) have adapted 
tissue engineering matrices and drug delivery depots for the controlled delivery of siRNA. The 
choice of local delivery material is important as it may serve as dual functions as the siRNA depot 
maintaining a therapeutically relevant dose in the pathological environment and serve as a tissue 
engineering scaffold guiding cell infiltration and growth.  
 
Regenerative Medicine Considerations  
The choice of material for local delivery plays a large role in dictating biologic response. 
The materials alone may influence the regenerative potential of their surrounding tissue [161] and 
synergism may result between a properly designed material and carefully selected target gene 
(section 2.7). Natural extracellular matrix (ECM) may seem an ideal candidate for tissue 
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regeneration, however, other materials may be better suited that have more interconnected pore 
structure, better degradation rates, and other beneficial properties that accelerate tissue 
regeneration [46]. The material should provide the best possible environment for the target tissue 
and the material should be entirely resorbable and biodegradable as to avoid further surgical 
inteverentions and material removal [162]. The mechanical properties of the material are an 
important design consideration and should be matched carefully with the desired tissue which 
vary widely in mechanical properties (bone, myocardium, skin). The mechanical properties should 
provide an ideal environment for cell ingrowth and differentiation. Importantly, the degradation 
rate of the matrix should be matched to the rate of tissue in-growth to serve as an appropriate 
template [46, 163]. The pore size of the material can dictate cell fate and properly tuned porosity 
may benefit tissue regeneration [164].  Using biomaterials for tissue engineering is a complex 
topic dictated by a variety of factors including choice of material, mechanical properties, 
degradation rates, and porosity [161] and these factors should be weighted when selecting a 
material. 
Our group has utilized polyester urethanes (PEUR), a promising class of synthetic 
biomaterials that have several of the above advantages including being injectable, tissue 
adherent, biocompatible, and biodegradable into biocompatible side products at rates dictated by 
the composition of the polyester triol and the isocyanate [24, 25].  PEURs provide mechanical 
support for tissue regeneration in excisional cutaneous wounds and bone defects [24, 165-167]. 
For clinical translatability, the use of lysine-derived polyisocyannates in the PEURs allow the 
scaffolds to be fabricated in situ with a reactive foaming process that has a rapid curing time filling 
unusual defects and allowing injectability [168, 169].  
 The choice of biomaterial scaffold is an important design consideration as the extracellular 
environment of neighboring and infiltrating cells may direct cell behavior and provide biologic 
cues. Further biologic direction may be forced through the incorporation of cells (e.g. stem cells) 
and biomacromolecules including siRNA.  
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Local Drug Depots for siRNA Delivery 
Though the enzymatic action of siRNA generates potent gene silencing, the activity has a 
finite half-life.  In rapidly dividing cells, a maximum silencing effect is noted near two days post-
transfection [17] with gene silencing nearly absent in one week [18]. To address this issue in 
regenerative medicine, it has been proposed to sustain the delivery to a local environment from 
a tissue-engineering scaffold injected or implanted into a wound. Table 2.1 summarizes recent 
efforts in the material based local delivery of siRNA.  
One approach is to suspend siRNA transfection complexes within natural materials and 
hydrogels. The Alsberg group has developed injectable calcium crosslinked alginate, 
photocrosslinked alginate, and collagen based hydrogels and demonstrated strong GFP silencing 
in incorporated cells in vitro [19]. More recently, they used photocrosslinked dextran hydrogels 
and covalently incorporated cationic linear polyethyleneimine (LPEI) to achieve tunable and 
sustained siRNA release [170]. The Saadeh lab applied an agarose matrix system containing a 
liposomal siRNA transfection complex and have shown proof of principle in vivo with mapk1 and 
lamin A/C and have shown therapeutic potential delivering siRNA against PHD2, p53, and Smad3 
[21, 22, 171]. 
 Synthetic materials have been used for controlled delivery of siRNA to local environments 
with drug delivery depots. The Mikos group has used PLGA microspheres for controlled siRNA 
delivery to a model of temporomandibular joint inflammation and achieved sustained release over 
the course of two weeks [172, 173]. Song and co-authors have developed an injectable polyplex 
hydrogel comprised of poly(organophosphazene) and either PEI or a CPP as a transfection 
reagent [174, 175]. Importantly, they demonstrated sustained release to a local tumor 
environment in vivo and reduction in tumor volume. The Hammond group has been developing 
materials for sustained siRNA delivery to local wound environments by utilizing their layer-by-
layer technology to electrostatically entrap calcium phosphate siRNA nanoparticles and deliver to 
a wound bed [176] . 
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Table 2.1 – Local delivery strategies for siRNA 
 Local Delivery Strategy 
Intracellular 
Delivery 
Strategy 
Release Kinetics and Activity Reference 
N
a
tu
ra
l 
M
a
te
ri
a
ls
 
Agarose 
Liposomal 
Complex 
Fast release, requires 
reapplication, various gene 
silencing >50% in vivo 
(J. W. Lee et al., 2010; P. 
D. Nguyen et al., 2010; 
Thanik et al., 2007; 
Wetterau et al., 2011) 
 [21, 22, 171, 225] 
Alginate, Photoalginate, or 
collagen hydrogel 
PEI or 
Chitosan 
Release on the order of days 
tunable by the material.  Gene 
silencing >90% in vitro. 
(Krebs et al., 2009) 
[19] 
Photocrosslinked dextran 
Hydrogel 
PEI 
Tunable Release around 1 week. 
Gene silencing >90% in vitro 
(K. Nguyen et al., 2013) 
[170] 
Collagen hydrogel dPAMAM 
Rapid release ~1 day. Gene 
silencing ~50% in vitro. 
(Vinas-Castells, Holladay, 
di Luca, Diaz, & Pandit, 
2009) [20] 
Chitosan hydrogel Chitosan 
Release not measured. Gene 
silencing >70% in vivo. 
(Han et al., 2011) 
[226] 
S
y
n
th
e
ti
c
 M
a
te
ri
a
ls
 
PLA-DX-PEG pellets PLA-DX-PEG 
Release around 1 week. Gene 
silencing >70% in vivo. 
(Manaka et al., 2011) 
[198] 
PCLEEP nanofibers Transit TKO 
Sustained release over 10-15 days. 
Gene silencing ~30% in vitro. 
(Rujitanaroj, Wang, Wang, 
& Chew, 2011) [227] 
Nylon coated Layer-by-
layer assembly 
Calcium 
phosphate 
nanoparticles 
Sustained release for 7-10 days. 
Gene silencing ~70% in vitro. 
(Castleberry et al., 2013) 
[176] 
Polyurethane 
Stimuli-
sensitive 
Polymers 
Controllable for 35 days, >90% 
silencing in vivo. 
(C. E. Nelson et al., 2012; 
C. E. Nelson et al., 2014) 
[158, 181] 
PLGA Microspheres PEI 
Fast release (<1d) of complexes. 
Sustained siRNA release for 20d. 
Gene silencing 30-40%. 
(Mountziaris et al., 2011; 
Mountziaris et al., 2012) 
[172, 173] 
PLGA Nanofibers Chitosan 
Sustained release for 30-35 days. 
Gene silencing ~50%. 
(M. L. Chen et al., 2012) 
[228] 
PEI-
poly(organophosphazene) 
Hydrogel 
PEI 
Sustained release for ~21 days. 
Gene silencing ~90% in vitro. 
(Y. M. Kim et al., 2012, 
2013) [174, 175] 
PEG Hydrogel PEI 
Dose requirement is too high for 
material 
(Takahashi, Wang, & 
Grainger, 2010) [229] 
 
Another promising approach is applying synthetic scaffold based matrices as a drug 
delivery depot and tissue template. Our group has adapted tissue engineering polyurethane as a 
local depot for siRNA delivery. The polyurethane materials were previously developed as a tissue 
engineering material and adapted for the sustained delivery of a variety of biomacromolecules 
including insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), basic fibroblast 
growth factor (bFGF), recombinant human bone morphogenic protein 2 (rhBMP-2), platelet-
derived growth factor (PDGF), and the antibiotic vancomycine [24, 165, 166, 177, 178]. We have 
demonstrated sustained silencing in mouse subcutaneous implants lasting at least 35 days (the 
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last time point measured with 90% silencing) and have shown therapeutic potential by silencing 
a regulator of angiogenesis, prolyl hydroxylase domain protein 2 (PHD2). 
As section 2.5 discussed, siRNA requires an intracellular delivery scheme, so the 
compatibility of intracellular delivery scheme with the local delivery material must be taken into 
consideration. For example, PEI/DNA complexes have been shown to be unstable when 
incorporated into hydrogel scaffolds and require stabilizing agents to retain activity [179, 180]. 
Similarly, siRNA complexes were shown to have a 50% activity loss unless stabilized [158, 181]. 
Substrate Mediated Delivery 
By immobilizing nucleic acids on a surface, the concentration of nucleic acid in the cellular 
microenvironment is increased leading to a 10-100 fold increase in transfection efficiency [182- 
184]. This concept termed ‘substrate-mediated delivery’ mimics the cellular internalization 
scheme of viruses that attach to extracellular matrix proteins to enhance cellular internalization 
[185, 186]. Immobilized nucleic acids are internalized through many modes of endocytosis, 
though caveolae-mediate endocytosis may play the largest role in substrate mediated plasmid 
delivery [187]. For comparison, substrate mediated delivery of a plasmid from a synthetic tissue-
engineering scaffold generated expression for 28 weeks [188]. Sustained nucleic acid delivery 
has been investigated therapeutically in regenerative medicine with a VEGF plasmid that 
improved angiogenesis in mice [189].  The higher efficiency of substrate mediated transfection of 
plasmids and siRNA stands to benefit tissue engineering with long term modification of gene 
expression.  
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2.7 mRNA Targets 
 Due to the flexibility of siRNA 
against any gene target and the 
tunabiltiy of regenerative scaffolds, 
scaffold based RNAi may be widely 
applicable [196]. Several local 
applications for gene silencing have 
been covered in detail elsewhere 
including pathologies affecting the lungs, 
eye, nervous system, digestive system, 
and vagina [31]. Another potentially 
rewarding pursuit of local gene silencing 
is in primary tumor sites but is 
considered outside the scope for this 
review. There also may be potential for 
targeting genes related to infectious disease (e.g. herpes simplex virus 2 and respiratory syncytial 
virus) [197, 198]. Also, the differentiation of encapsulated stem cells may be guided by the 
inclusion of siRNA [199]. This discussion will be focused on gene silencing for tissue regeneration.  
 
Inflammation and Autoimmune Disorders 
Genes that are pro-inflammatory represent possible targets for tissue regeneration, 
specifically for wound healing. Local TNFα silencing has been shown to improve psoriasis by 
reducing epidermal thickness and normalizing skin morphology [200]. Also, local TNFα silencing 
has been shown to improve a rodent model of inflammatory bowel disease [201]. These studies 
provide proof of principle that TNFα silencing may decrease chronic inflammation and restore 
regenerative capacity. In the same vein CD16 was used in a model for temporomandibular joint 
Pathology Gene Reference 
Inflammation 
TNFα 
(Jakobsen et al., 
2009) (Y. Zhang et 
al., 2006) 
CD16 
(Mountziaris et al., 
2012) 
Autoimmune 
Tbox21 
(M. Nakamura, et al., 
2008) 
CD86 
(Ritprajak, et al., 
2008). 
Fibrosis and Scarring 
 
CTGF (Abraham, 2008) 
mTOR 
(H. Takahashi et al., 
2010) 
Smad3 
(J. W. Lee et al., 
2010) 
(Z. Wang et al., 2007) 
erk2 
(C. Zhang et al., 
2014) 
TGFβ 
(J. S. Huang et al., 
2002) (H. Nakamura 
et al., 2004) 
Cell Cycle 
p53 
(P. D. Nguyen et al., 
2010) 
p21 
(Bedelbaeva et al., 
2010) 
Bone Regeneration Noggin (Manaka et al., 2011) 
Muscle Regeneration Myostatin 
(Kawakami et al., 
2013) 
Tendon Regeneration Col5α1 (P. Lu et al., 2011) 
Table 2.2 Gene targets for regenerative medicine 
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(TMJ) inflammation and decreased TMJ induced changes in meal patterns and also decreased 
downstream interleukin-6 expression [173].  These studies suggest that TNFα or CD16 may be 
beneficial targets in regenerative medicine and wound healing. Immune recognition of synthetic 
or naturally derived materials may create serious complications. RNAi may be a high impact 
mediator of immune responses to materials. A few examples include T-box21 and CD86 silencing. 
Alopecia areata was treated with T-box21 siRNA conjugated to cationized gelatin in a mouse 
model resulting in hair shaft elongation [202]. CD86 siRNA applied topically reduced local 
inflammation and may be a potential strategy for treating allergic skin disease [203].  
 
Tissue Specific Regeneration 
Tissue specific regeneration may be encouraged by silencing genes that encourage 
differentiation of specific cell types. Bone formation has been encouraged using siRNA targeting 
Noggin mRNA [192] . In this study, bone morphogenic protein 2 (BMP-2) and siRNA against 
Noggin were included in poly-D,L-lactic acid-p-dioxanone-polyethylene glycol block co-polymer 
(PLA-DX-PEG) hydrogels which encouraged ectopic bone formation over controls [192]. It is 
feasible to use similar designs to assist bone regeneration and fill critical size bone defects. By 
injecting myostatin-siRNA nanoparticles with atelocollagen, skeletal muscles of a mouse model 
of muscular dystrophy were increased in size and electromyography indicated increased muscle 
activity [204]. This result motivates the use of myostatin siRNA in further studies to regenerate 
weak or absent muscle tissue. Collagen V has been shown to negatively regulate the size of type 
I collagen fibers and fibril diameter is inversely proportional to the collagen V concentration. By 
silencing Col5α1 mRNA in tenocytes and combining with normal tenocytes, collagen fibrils 
increased in size and improved tendon tissue regeneration [205]. 
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Fibrosis and Scarring  
 Fibrosis and scarring to date have the largest number of genes studies to decrease the 
fibrotic response and improve the quality of the regenerated tissue. Connective tissue growth 
factor (CTGF) is a logical target that is overexpressed in scarred wounds. CTGF inhibition results 
in type I and III collagen decreases and attenuated liver fibrosis [206]. Though there are no studies 
using CTGF siRNA in scarless wound healing, it is a logical target to promote healing with less 
fibrotic wounds. Mammalian target of rapamycin (mTOR) is another potential target that when 
silenced in vitro decreases fibrotic markers. However, in vivo silencing in this study did not show 
significance. The authors expect this is due to low loading capacity of the hydrogel system [207]. 
TGF-β antagonists have been shown to reduce scarring and fibrosis and accelerate wound 
healing [208] so using RNAi to target TGF-β type II receptor resulted in inhibited fibronectin 
assembly and decreased cell migration. In vivo, TGF-β type II receptor inhibition reduced matrix 
deposition [209]. As an additional target, TGF-β may be dependent on Smad3 and when 
decreased with RNAi reveals a significant reduction in epidermal thickness and collage deposition 
in an ionizing radiation mouse model [22]. Another study has shown that Smad3 siRNA can 
decrease procollagen expression in keloid fibroblasts by interrupting TGF-β [210]. Finally, 
inhibition of ERK2 by siRNA reduced epidural fibrosis in a laminectomy model in rats by 
decreasing fibroblast proliferation preventing epidural scar adhesion [211]. 
 
Cell Cycle Control 
The cell cycle regulator, p53, was silencing in diabetic mouse excisional wounds delivered 
from an agarose matrix which resulted in accelerated wound closure, an increase in CD31 cell 
staining, VEGF secretion, and SDF-1 expression [21]. To our knowledge, p21 silencing in 
regenerative medicine has not yet been performed. However, a p21 knockout mouse was able to 
regenerate ear holes suggesting a link between the cell cycle regulator p21 and appendage 
regeneration [212]. Though cell cycle regulators may be a dangerous target gene for systemic 
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silencing due to potential carcinogenic effects, they may prove to be an effective gene target for 
local and temporary silencing to improve tissue regeneration.  
 
Angiogenesis (PHD2) 
 Angiogenesis is delayed or absent in pathological wound healing [213] and the increase 
of angiogenesis represents a logical approach for the improvement of diabetic wounds. PHD2 is 
an endogenous negative regulator of the transcription factor hypoxia-inducible factor-1α (HIF-1α), 
and PHD2 inhibition increases HIF-1α activity (Fig. 2.3) [214, 215]. This occurs through the 
hydroxylation of the proline residues Pro402 and Pro564 of HIF-1α [216]. It has been shown that 
PHD2 has a much higher impact than PHD1 or PHD3 in human cells [8] and the potent knockdown 
of PHD2 results in a large up-regulation of the transcription factor HIF-1α and its downstream 
genes VEGF, fibroblast growth factor 2 (FGF-2), endothelial nitric oxide synthase (eNOS), 
angiopoieten (ANGPT), and stromal cell-derived factor 1 (SDF-1) [217, 218]. These factors 
orchestrate both formation and maturation of vessels and, in the case of SDF-1, recruit endothelial 
progenitors that further promote local vasculogenesis [219]. Previous pro-angiogenic approaches 
have employed a single growth, factor, such as vascular endothelial growth factor (VEGF), which 
does not fully recapitulate the complex regulatory mechanisms involved in neovascularization and 
results in immature, leaky vasculature that is susceptible to rarefaction [220].  To compensate, a 
proof-of-concept material platform delivered multiple growth factors with precise temporal control 
resulting in angiogenesis, vessel maturation, and vascular remodeling [221]. However, growth 
factor delivery is expensive and the material platform to deliver such temporal control is 
cumbersome. Therefore, siRNAi-mediated silencing of PHD2 is a promising approach for pro-
angiogenic therapy 
Our Group and others have shown that PHD2 inhibition promotes therapeutic 
neovascularization of ischemic tissues and can promote tissue repair and tissue scaffold 
vascularization and integration [222-224]. Further, others have shown stabilization of HIF1α is 
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critical in wound healing and therapeutic intervention may reverse the negative effects of 
hyperglycemia in diabetes [225]. 
 
Figure 2.3 – PHD2 Signaling in Normoxia and Hypoxia. During normoxia, the oxygen dependent PHD2 
hydroxylates proline residues in HIF-1α leading to its recognition by the Von Hippel-Lindau Tumor 
suppressor (pVHL) and results in the proteosomal degradation. Alternatively during hypoxia, PHD2 is 
inactive and HIF-1α is free to translocate to the nucleus with HIF-1β and begin transcription of pro-
angiogenic genes. 
 
2.8 Outlook 
The promise of therapeutic siRNA has already been adapted for clinical trials in a variety 
of indications ranging from respiratory syncytial virus infection, macular degeneration, hepatitis B, 
renal failure, macular oedema [14], pachyonychia congenital [15], macular degeneration [226], 
skin disorders [227], and targeted delivery to melanoma [16, 228, 229].  There are 22 clinical trials 
in all when this review was compiled [28] and many more in the development pipeline. With 
properly designed material delivery platforms and new molecular based targets identified, 
powerful RNAi based therapies for regenerative medicine may be within reach.  
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Chapter 3 
Aim 1 – In vitro Development of PEUR-NP Platform 
Text for Chapter 3 taken from: 
Nelson CE, Gupta MK, Adolph EJ, Shannon JM, Guelcher SA, Duvall CL. “Sustained local 
delivery of siRNA from an injectable scaffold.” Biomaterials. 2012; 33(4): 1154-61 
 
3.1 Introduction 
 The discovery of RNA interference [12] motivated extensive efforts toward harnessing 
gene-silencing biomacromolecules for clinical therapeutic use. Small-interfering RNA (siRNA) has 
rapidly advanced into clinical trials for indications such as macular degeneration [226], skin 
disorders [227], and targeted delivery to melanoma [16, 228, 229].  The current work focuses on 
development of a platform technology to be used for the controlled, local delivery for regenerative 
medicine, which is a less mature but promising application area for siRNA [26].   
 Effective delivery has been the primary limitation to more rapid and widespread adoption 
of siRNA for clinical use due to its susceptibility to nucleases and poor intracellular cytosolic 
delivery [230].  A variety of strategies have been developed to protect siRNA and improve 
intracellular delivery including electrostatic complexation with cationic lipids, polymers, and 
polysacaccharides, as well as conjugation to cell-penetrating/fusogenic peptides, dendrimers, 
antibodies, vitamins, and nanoparticles [64, 231-240]. Controlled polymerization techniques such 
as reversible addition-fragmentation chain transfer (RAFT) polymerization offer a promising 
approach to designing synthetic polymers that are monodispersed, and contain spatially-defined 
functionalities [241, 242], and the current work employs a RAFT-synthesized, pH-responsive 
polymer-based micellar nanoparticle (si-NP) recently optimized for efficient and biocompatible 
intracellular siRNA delivery [23, 133].   
 The polyplex, bioconjugate, and nanoparticulate siRNA carriers that have advanced to in 
vivo preclinical testing have been primarily delivered intravenously or through local injection (i.e., 
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intratumoral) in PBS.  For tissue regeneration applications, it is anticipated that it will be desirable 
for siRNA activity to be locally sustained and mediated from a biocompatible and biodegradable 
tissue template. Because siRNA activity is typically transient and can be exhausted by one week 
in rapidly dividing cells [17, 18], natural materials including alginate, collagen and agarose have 
been applied for sustained delivery of siRNA [19-22].  Pre-fabricated synthetic scaffolds made 
from ε-caprolactone and ethyl ethylene phosphate copolymer (PCLEEP) nanofibers have also 
been pursued for the release of siRNA/transfection reagent (TransIT-TKO) complexes and have 
been shown to achieve sustained delivery of bioactive siRNA for 28 days [193].     
 Porous, biocompatible, and biodegradable polyester polyurethanes (PUR) comprise a 
promising class of synthetic injectable biomaterials that can provide both mechanical support and 
also controlled drug release to regenerating tissues [167].   Several drugs,  including insulin-like 
growth factor-1 (IGF-1), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), 
recombinant human bone morphogenetic protein 2 (rhBMP-2), platelet-derived growth factor 
(PDGF), and the antibiotic vancomycin have been incorporated into and delivered from PUR 
scaffolds [24, 165, 166, 177, 178].  Additionally, PURs support the ingrowth of cells in excisional 
cutaneous wounds [24] and bone defects [165, 166]. Further advantages of PURs are that they 
adhere to tissue, do not stimulate inflammation [24], and biodegrade into biocompatible side 
products at rates that can be tuned based on the polyester triol and isocyanate precursor 
compositions [25].  Importantly, the use of lysine-derived polyisocyanates in the PUR scaffolds 
makes them more clinically translatable because they can be synthesized using a two-component 
foaming process that allows a short manipulation time for filling of any shape or size defect, 
followed by rapid curing in situ [168, 169]. 
 The current study pursues a novel application of PURs to deliver pH-responsive micellar 
si-NPs designed for the intracellular delivery of siRNA.  This investigation validates homogenous 
loading of siRNA nanocarriers within the PUR scaffold, sustained, diffusion-controlled release of 
intact nanoparticles, and maintenance of gene silencing bioactivity of the released si-NPs. 
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3.2. Methods  
Materials 
All chemicals were purchased from Sigma-Aldrich (Milwaukee, WI, USA) except the 
following.  Purchase of siRNA was from Applied Biosciences (Ambion), LDH cytotoxicity kit from 
Roche, Hiperfect transfection reagent (positive control) from Qiagen, and PD10 desalting columns 
from GE healthcare.  Lysine Triisocyanate (LTI) was purchased from Kyowa Hakko Kogyo Co., 
Ltd. (Tokyo, Japan).  DMAEMA, and butyl methacrylate were vacuum distilled prior to use.  2,2’-
Azobis(2-methylpropionitrile) (AIBN) was recrystallized twice with methanol. 
 
Synthesis of 4-cyano-4{[(ethylsulfanyl)carbonthioyl]sulfanyl}pentanoic acid (ECT) 
The RAFT chain transfer agent ECT was synthesized following protocols previously 
described by Convertine et al. [23] adapted from Moad et al. [243].  Briefly, Ethanethiol (76 mmol, 
4.72 g) was reacted with carbon disulfide (79 mmol, 6.0 g) in the presence of sodium hydride (79 
mmol, 3.15 g) in diethyl ether for 1h. The resulting sodium S-ethyl trithiocarbonate was further 
reacted with iodine (25 mmol, 6.3 g) to obtain bis(ethylfulfanythiocarbonyl) disulfide, which was 
further refluxed with 4,4’-azobis(4-cyanopentanoic acid) in ethylacetate for 18 h.  The crude ECT 
was purified by column chromatography using silica gel as the stationary phase and ethyl 
acetate:hexane (50:50) as the mobile phase. 1H NMR (400MHz, CDCl3):  1.36 t (SCH2CH3);  
1.88 s (CCNCH3);  2.3–2.65 m (CH2CH2);  3.35 q (SCH2CH3). 
 
Synthesis of 2-propyl acrylic acid (PAA)  
The synthesis of PAA was adapted from existing methods [244]. In brief, diethyl 
propylmalonate (200 mmol, 40.45 g) was stirred in 1M KOH in 95% ethanol and acifidied with HCl 
to yield 2-carbopropoxybutyric acid, which was reacted with diethylamine (200 mmol, 14.62 g) 
and formalin (200 mmol, 16.11 g) at room temperature for 24h, followed by reflux at 60°C for 8 
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hours.  After acidification, the resulting 2 propylacrylate was refluxed in 2M KOH for 20 h to yield   
2-propyl acrylic acid, which was extracted, dried, and vacuum distilled under vacuum to yield a 
colorless oil. 1H NMR (400 MHz, CDCl3)  0.97 t (CH3CH2);  1.55 m (CH3CH2CH2);  2.31 t 
(CH3CH2CH2);  5.69-6.32 q (CH2=C);  12 s (CCOOH) .  
 
Synthesis and characterization of pDMAEMA macro CTA 
The synthesis of the poly[2-(diethylamino)ethyl methacrylate] pDMAEMA macro chain 
transfer agent (mCTA) was conducted by RAFT polymerization using conditions adapted from 
[23].  Based on a polymerization kinetics experiments (Appendix Fig. A1), the RAFT 
polymerization was conducted at 70 °C under a nitrogen atmosphere for eight hours with 1,4-
dioxane as the solvent (70% by weight), an initial monomer to CTA ratio of 100, and a CTA to 
initiator ratio of 10.  The pDMAEMA mCTA was isolated by precipitation into n-hexane (x3) and 
dried overnight.  The polymer was analyzed by gel permeation chromatography (GPC, Shimadzu 
Crop., Kyoto, Japan) with an inline Wyatt miniDAWN TREOS light scattering detector (Wyatt 
Technology Corp., Santa Barabara, CA) and 1H nuclear magnetic resonance spectroscopy (NMR, 
Bruker 400Mhz Spectrometer equipped with 9.4 Tesla Oxford magnet) for molecular weight and 
polydispersity.   
 
Synthesis and characterization of DMAEMA-b-(PAA-co-BMA-co-DMAEMA)  
RAFT polymerization was utilized to synthesize the second block as previously described 
[23].   Additional monomers butyl methacrylate (BMA), PAA, and DMAEMA were added to the 
pDMAEMA mCTA chain with an initial monomer to mCTA ratio of 250 in stoichiometric quantities 
of 50% BMA, 25% PAA, and 25% DMAEMA.  The initiator AIBN was used with a mCTA to initiator 
ratio of 5.  The polymerization was conducted for 18 hours under a nitrogen atmosphere at 70oC.  
The resulting polymer was isolated by precipitation into chilled 50:50 ether:pentane, redissolved 
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in acetone and precipitated into chilled pentane twice, and vacuum dried overnight.  The polymer 
was then dissolved in a minimal amount of ethanol, diluted into dH2O, and further purified using 
PD10 desalting columns (GE Healthcare).  The eluent was frozen and lyophilized yielding a pure 
polymer powder.  The polymer was analyzed by GPC for number average molecular weight (Mn) 
and polydispersity.  NMR in CDCl3 and D2O was used to determine composition and verify the 
formation of micelles with a DMAEMA corona.  Transmission Electron Microscopy (TEM, Philips 
CM20 Transmission Electron Microscope, EO, Netherlands) and Dynamic Light Scattering (DLS, 
Zetasizer nano-ZS Malvern Instruments Ltd, Worcestershire, U.K.) were used to confirm presence 
and size of micelles, to determine the critical micelle concentration, and to characterize micelle 
pH-responsiveness. Carbon TEM grids (Ted Pella Inc. Redding, CA) were spotted with 5uL of 
polymer solution (~50ug/mL) and dried under vacuum for 24 hours. 
 
Formation and Characterization of siRNA-loaded Micellar Nanoparticles  
siRNA was dissolved in nuclease free water, and  si-NPs were formed by injecting siRNA 
in nuclease free polypropelene tubes, diluting with PBS, adding polymer in PBS, and incubating 
at room temperature for 30 minutes.  si-NPs were formulated based on the charge ratio defined 
as the number of positively charged tertiary amines (assumed to be 50% at physiologic pH) on 
the DMAEMA block (N) to the number of negatively charged phosphate groups on the backbone 
of siRNA (P).  Complexes were formed anywhere between 0.5 and 8 N/P.  A 2% agarose gel was 
prepared with 0.5 μg/mL ethidium bromide and allowed to gel at room temperature.  si-NPs and 
controls were run for 40 minutes at 100 V.  This experiment was also conducted after pre-
incubating the si-NPs in 50% serum to verify serum stability.  Dynamic light scattering and 
potential were used for physicochemical characterization of the si-NPs, and TEM was used to 
further verify si-NP size and morphology. 
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Synthesis of si-NP-loaded PUR Scaffolds 
Polyester triols were synthesized as previously described from a glycerol starter targeting 
900 Da and a backbone comprising 60 wt% ε-caprolactone, 30 wt% glycolide, and 10 wt% D,L-
lactide [24, 245, 246].  si-NPs were synthesized as described above using an N/P of 4 and 4 nmol 
of fluorescently labeled (6-FAM) siRNA against GAPDH or non-labeled siRNA with a scrambled 
sequence.  si-NPs were frozen and lyophilized and the resulting powder was rigorously mixed 
into 134 μmol of the polyol component of PUR using a Hauschild DAC 150 FVZ-K SpeedMixer 
(FlackTek, Inc., Landrum, SC).  A slight excess of lysine triisocyanate (387 μmol) was then added 
and scaffolds were allowed to cure at room temperature forming a porous PUR foam over 
approximately 10 minutes. 134 μmol of water was included in the polyol because it reacts with 
LTI to produce CO2 which acts as a blowing agent and creates pores in the scaffold.  The resulting 
200 mg foams were sectioned into discs with a diameter of 13mm and a thickness of 
approximately 3mm. 
 
PUR Characterization 
Confocal microscopy (Zeiss LSM 510Meta) equipped with differential interference contrast 
(DIC) was used to analyze the distribution of si-NPs in the scaffold. The 13mm diameter by 3mm 
cylindrical foams were immersed in 1mL of PBS in a 24 well plate.  Releasate was collected at 
regular intervals approximating an infinite sink condition, and release data were fit to the Weibull 
function [166, 247].  Releasate was analyzed by TEM and DLS for presence and size of released 
si-NPs.   
 
Cell Culture and siRNA Knockdown 
Mouse Embryonic Fibroblasts (NIH3T3) were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Gibco Cell Culture, Carlsbad, CA) supplemented with 5% Bovine Calf Serum 
(BCS, Gibco), and 1% penicillin-streptomycin (Gibco).  For gene silencing experiments, NIH3T3 
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mouse embryo fibroblasts were seeded at a density of 12,500 cells/cm2 in a 12 well plate and 
allowed to adhere overnight.  Fresh NPs or released NPs were added in fresh media with a final 
concentration of 6.25nM to 50nM siRNA and allowed to incubate for 24 hours.  Each group was 
analyzed with n=3, and each replicate was run in triplicate during qRT-PCR.  The cells were lysed 
and homogenized with QIAshredder (Qiagen), and RNA was purified using the RNeasy® Mini Kit 
(Qiagen).  RNA quantity and quality was assessed with a nanodrop spectrophotometer ND-1000 
(Thermo Scientific).  cDNA was synthesized with iScriptTM cDNA synthesis kit (BIO-RAD) on a 
C1000TM thermal cycler. Quantitative PCR was done using IQTM Real Time SYBR Green PCR 
Supermix on a quantitative thermal cycler (Bio-Rad iCycler iQ).  GAPDH expression was 
normalized to β-Actin expression using the ΔΔCT method.  Primers used were: β-actin Forward 
5’-CTACGAGGGCTATGCTCTCCC-3’, β-actin backward 5’-CGTCCTCATGCTACTCAGGCC-3’, 
GAPDH Forward 5’-CTCACTCAAGATTGTCAGCAATG-3’, GAPDH Backward 5’-
GAGGGAGATGCTCAGTGTTGG-3’. 
 
Imaging of Cell Uptake of si-NPs Post-release from PUR Scaffolds 
NIH3T3s were seeded at 12,500 cells/cm2 in 8 well chamber slides and incubated for 4 
hours with FAM labeled siRNA containing si-NPs released from PUR scaffolds.  The media was 
removed, and the cells were washed 3x with PBS and fixed in 4% paraformaldehyde for 30 
minutes. After 2 washes in PBS, cell nuclei were counterstained with Hoechst 33258 (5 μg/mL, 
Sigma) and then washed an additional 3x.  Images were acquired on a fluorescent microscope. 
 
Cytotoxicity 
NIH3T3 cells were seeded at a density of 12,500 cells/cm2 in a 96 well plate and allowed 
to adhere overnight.  si-NPs were then added in fresh media and allowed to incubate for 24 hours. 
The cells were then lysed and analyzed for intracellular LDH with a Cytotoxicity Detection Kit 
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(Roche Applied Science) as previously described [248], and a plate reader (infinite F500, Tecan 
Group Ltd., Mannedorf, Switzerland) set for absorbance at 492nm with reference at 595nm. 
Statistical analysis 
All data are reported as means ± standard error of the mean (SEM).   Analysis of Variance 
(ANOVA) was used to determine treatment effects and p<0.05 was considered significant. 
 
3.3. Results  
 
Fig 3.1Chemical composition of materials used for siRNA delivery. (A) Chemical structure of the 
micelle-forming, pH-responsive diblock copolymer used for siRNA packaging and intracellular delivery. The 
homo-DMAEMA first block was designed for siRNA condensation due to the positive charge on the tertiary 
amines. The second block is pH-responsive and tuned for endosomal escape due to micelle destabilization 
and endosomolytic activity triggered by protonation of PAA and DMAEMA. (B) Chemical structure of 
polyurethane precursors. LTI reacts with the –OH groups of the polyol to form urethane bonds and create 
the PUR network. 
 
Polymer synthesis and characterization 
4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylvpentanoic acid (ECT) was synthesized as 
previously described [23].  2-propyl acrylic acid (PAA) was synthesized using established 
methods [244].  RAFT polymerization was used to synthesize a mCTA of DMAEMA (Mn = 
11200g/mol, PDI = 1.40, (Appendix Fig. A2). The pDMAEMA mCTA was used to polymerize a 
second block with a resultant Mn of 32040 g/mol for a total Mn of 43240 g/mol (PDI = 1.41) as 
shown in Appendix Fig. A2.  1H-NMR was used to confirm the percent composition of the second 
block which was determined to be 30%PAA, 25%DMAEMA, and 45%BMA (Appendix Fig. 3A).   
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When dissolved in D2O, 1H-NMR peaks from the core-forming terpolymer are suppressed, 
verifying the formation of micelles in an aqueous environment. (Appendix Fig. 3B).  The polymer 
structure is depicted in Fig. 3.1.  
 
Fig 3.2 Physicochemical characterization of freshly prepared and PUR-released si-NPs. (A) Dynamic 
light scattering demonstrated that si-NP diameter was around 40-nm at N/P ratios of 2 or greater, and at 
N/P = 1, the charge neutrality caused the NPs to be less stable and larger. This is further represented by 
the ζ-potential, which was slightly negative at N/P of 1, 8.3 mV at N/P of 2, and approximately 20 mV at all 
N/P of 4 or greater. (B) The TEM image confirmed the micellar architecture and size of fresh si-NPs (top). 
Releasate si-NPs had a larger diameter of approximately 100 nm as shown both by DLS and TEM (B, 
bottom), and PUR-released si-NPs also had significantly reduced ζ-potential that was approximately charge 
neutral. 
 
si-NP synthesis and characterization 
Micellar nanoparticles were self-assembled in an aqueous environment and characterized 
for size and morphology by DLS and TEM respectively.  TEM and DLS (Fig. 3.2) report similar 
diameters of 31 nm and 39.6 nm respectively, with the smaller diameter seen with TEM being due 
to micelle dehydration.  DLS of serially diluted samples revealed a critical micelle concentration 
(CMC) below 2g/mL, based on a DLS-detected loss of micelle stability (Fig. 3.3A).  DLS was 
also used to demonstrate the dependency of the CMC on pH.  The results confirm that micelle 
structure was destabilized at pH 5 at a concentration of 100 g/mL, which is important for micelle 
endosomolytic behavior (Fig. 3.3B) [133]. Gel electrophoresis determined serum stable 
complexation of siRNA into si-NPs across a range of N:P ratios (Appendix Fig. A4). 
 42 
si-NP-loaded PUR scaffolds 
PUR foams were synthesized by 
reacting polyester triols (polyol) with lysine 
triisocyanate forming the porous 
polyurethane foam (Fig. 3.1B).  
Differential interference contrast 
microscopy (DIC) of PUR scaffolds 
revealed an intact, connected porous 
structure (Fig. 3.4B,E) with a mean pore 
diameter of 150μm ± 64μm.  Confocal microscopy shows a relatively homogenous distribution of 
fluorescently labeled siRNA containing NPs throughout the PUR matrix (Fig. 3.4A-C) comparable 
to the distribution seen in the PUR containing naked siRNA (Fig. 3.4D-F).    
 
siRNA-NP Release Kinetics and Modeling 
Release from the scaffold was quantitatively assessed using si-NPs made with 
fluorescently labeled siRNA.   Approximately 20% of the payload was released in the first 12 hours 
followed by a sustained release approaching 80% cumulative release by 21 days (Fig 3.5).  
Conversely, the much smaller naked siRNA diffuses from the scaffold much faster than si-NPs, 
reaching nearly 100% in 3 days. Importantly, TEM and DLS of releasate demonstrated that intact 
si-NPs, although of larger diameter than fresh si-NPs (approximately 100nm), were delivered from 
the PUR scaffolds (Fig. 3.2).   
The Weibull function has been previously used to evaluate the drug release mechanisms 
of drug eluting matrices that efficiently release their payload (cumulative release exceeding 60%) 
[166, 247].  The release of si-NPs was fit to the Weibull empirical model in Equation 3.1: 
 
Fig 3.3 Micelle stability is dependent on 
concentration and pH. (A) critical micelle 
concentration (CMC) determination using DLS 
demonstrated disruption of micelles occurred at 
2 μg/mL. (B) DLS also revealed pH-dependent 
destabilization of the micelles at pH = 5 at a 
concentration of 100 μg/mL. 
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𝐸𝑞𝑛 3.1:          
𝑀𝑡
𝑀∞
= 1 − exp(−𝑎 ∙ 𝑡𝑏) 
where Mt is the mass of si-NPs released at time t, M∞ is the total mass of si-NPs, a is a constant 
based on the system, and b is a constant based on the release kinetics.   
 
 
Fig 3.4 FAM-labeled siRNA and si-NPs distribution within the PUR scaffold. Comparison of fluorescent 
confocal images of PUR scaffolds loaded with FAM-labeled siRNA or si-NPs. Row 1 is a scaffold loaded 
with naked siRNA. Row 2 is a scaffold loaded with si-NPs. The 3rd row is an empty scaffold to verify that 
there is no green auto-fluorescence of the PUR scaffold. Note that scaffold pores contain no fluorescence, 
and the distribution between naked siRNA and si-NPs is similar.  
 
Previous reports suggest that values of b < 0.75 indicate that Fickian diffusion is the 
dominant release mechanism [166, 247].  The values obtained from the best fit were found to be 
a=1.892, b=0.699, R2=0.995 for siRNA only and a=0.317, b=0.560, with R2 = .996 for si-NPs.   
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For additional evidence supporting diffusion-controlled release of siRNA, we performed a 
scaling analysis to compare the predicted and measured initial release rates. The Stokes-Einstein 
equation (Equation 3.2) and the Higuchi equation [249]  (Equation 3.3) were utilized together to 
further validate the diffusion-controlled release mechanism.  These equations, where D is the 
diffusivity, Mt is the rate of mass transfer, and r is the radius of the particle, provide relationships 
that allow the initial mass transfer rate to be related to the inverse of the square root of the radius 
of the solute: 
𝐸𝑞𝑛 3.2:         𝐷 ~
1
𝑟
 
𝐸𝑞𝑛 3.3:          𝑀𝑡 ~ √𝐷 
Assuming all conditions except hydrodynamic diameter are maintained constant between the two 
samples except yields the following scaling prediction: 
𝐸𝑞𝑛 3.4:      
𝑀𝑠𝑖𝑅𝑁𝐴
𝑀𝑠𝑖−𝑁𝑃
=  
√𝑟𝑠𝑖−𝑁𝑃
√𝑟𝑠𝑖𝑅𝑁𝐴
 
This analysis was completed assuming a hydrodynamic diameter of 2.56 nm for the siRNA, which 
was the value suggested by Barone et al for a 28 mer duplex RNA [250].  The hydrodynamic 
diameter of 38.69 nm that was experimentally determined using DLS for a charge ratio of 4/1 for 
si-NPs was used.  Based on the measured initial release of 17% for si-NPs and 66% for naked 
siRNA, the left side of Eqn. 4 reduces to 3.88 and the right side 3.87.  Thus the scaling analysis 
is consistent with the notion that the release of siRNA from the scaffolds is governed by Fickian 
diffusion.  
Cytotoxicity experiments showed that the si-NPs were cytocompatible at the doses used 
(Appendix Fig. A5).  Gene expression analyzed by qRT-PCR showed significant reduction 
(p<0.05) in mRNA levels for GAPDH mediated by releasate collected between 0-24h, 24-48h, 
and 48-96h, while controls containing scrambled siRNA showed no activity (Fig. 3.6A). Further 
experimentation showed that PUR-released si-NPs produced dose dependent silencing of 
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GAPDH expression with the highest dose of 50 nM producing approximately 50% gene 
knockdown (Fig. 3.6B) while freshly prepared si-NPs produced a dose dependent silencing with 
83% reduction at 50nM.   The finding that there was a strong correlation between dose and gene 
silencing, indicated a siRNA dependent effect, and importantly, scrambled siRNA controls had no 
observable activity. The microscopic observation of diffuse fluorescent siRNA in the cytoplasm of 
cultured cells confirmed the maintenance of endosomolytic behavior, cytoplasmic delivery, and 
bioactivity of the PUR-released si-NPs (Fig 3.6C).   
 
 
Fig 3.5 Release of siRNA and si-NPs from PUR scaffolds is diffusion controlled. The Weibull empirical 
model equation best-fit was determined and is overlaid here for each data set. Naked siRNA is rapidly 
released with an initial burst of over 60% at 12 h and is entirely released by 3 days. si-NPs have a slower 
rate of release with a burst release of less than 20% during the first 12 h, followed by sustained release 
that approaches 80% by 21 days. 
PUR-released si-NP 
3.4. Discussion  
Technologies that enable the efficient and sustained delivery of siRNA are a high-impact 
but relatively unmet need.  This is primarily due to the number and complexity of the delivery 
barriers that exist.  Here, a new platform is presented that is capable of both sustained and 
effective delivery of siRNA from a PUR scaffold capable of providing a biocompatible and 
biodegradable tissue template that can be cured in situ using a clinically-translatable injectable 
formulation. Due to nuclease susceptibility and membrane impermeability of naked siRNA, little 
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success has been found with carrier-free siRNA delivery methodologies, and thus, the siRNA was 
first loaded into the pH-responsive micellar si-NPs prior to formulation with the biomaterial matrix.   
 
Fig 3.6 Fresh and released si-NPs are delivered intercellularly and mediate gene specific silencing. 
qRT-PCR was used to measure expression of the model gene GAPDH relative to β-actin and then 
normalized to no treatment controls. (A) Bioactivity of freshly prepared and PUR-released si-NPs collected 
during the defined time frames 0–24 h, 24–48 h, and 48–96 h indicates that bioactivity of si-NPs released 
from the PUR is not significantly altered over time. Statistical significance relative to scrambled control 
siRNA containing si-NPs was noted at all time points (p < 0.05). (B) Dose response of PUR-released si-
NPs demonstrated a linear relationship (R2 = 0.999) between siRNA dose and silencing activity, suggesting 
an siRNA-dependent gene silencing effect. Minor reduction in siRNA bioactivity was apparent in PUR-
released si-NPs relative to fresh si-NPs. (C) Diffuse green fluorescence is noted in the cytoplasm of 
NIH3T3s after 4 h of incubation with PUR-released si-NPs. This presence of FAM-labeled siRNA in the 
cytoplasm confirmed effective siRNA cytoplasmic delivery.  
 
The RAFT synthesized polymer shown in Fig. 3.1A is the basis for the si-NPs and was 
specifically designed for improved cytoplasmic uptake, siRNA protection, and endosome escape 
[23, 133].  Toxicity of typically-utilized polyplexes made with cationic polymers [251] and the 
limitations associated with inefficient bioactivity due to lysosomal degradation or extracellular 
clearance [252] motivated the development of the polymer. si-NPs are formulated at positive 
charge ratios (typically 4:1) providing a net positive charge which facilitates efficient cell uptake 
by most cell types [253, 254].  Once in the endosome, decreasing pH destabilizes the micelle 
structure due to protonation of PAA and DMAEMA monomers and exposes the membrane-
disruptive core [255].  The configuration of the second block (Fig. 3.1A) is finely tuned to provide 
a sharp pH response at the desired pH by incorporating appropriate amounts of hydrophobic BMA 
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[256] and pH responsive DMAEMA and PAA. Fig. 3.3B confirmed the pH-dependent micelle 
destabilization using DLS and it is hypothesized that this destabilization allows the hydrophobic 
2nd block to penetrate and disrupt endosomal membranes and facilitate siRNA delivery to the 
cytoplasm [107, 130, 257, 258].  Once internalized, siRNA may be competitively dissociated from 
the polymer through interactions within the cytoplasm by other ionic molecules [253] thus gaining 
access to the RNAi machinery in the cytoplasm. 
Recently, biomaterials have been pursued for sustained siRNA delivery, with natural 
materials such as alginate, collagen and agarose being mostly used in these applications due to 
their biocompatibility [19-22].   However, these natural materials generally lack tunability and have 
been limited to rapid burst release of siRNA.   The best sustained delivery to date has been 
achieved using PCLEEP nanofiber scaffolds, however, the manufacture of the scaffold requires 
complex equipment (electrospinning apparatus) and must be pre-made to a defined size and 
geometry [193]. Therefore, there still remains a significant need for a more clinically translatable 
biomaterial that can conform to tissue defects of varied sizes and shapes where it will cure in situ 
and deliver siRNA locally in a sustained manner. 
  PUR scaffolds provide multiple advantages as a biomaterial for controlled drug delivery 
to tissue defects for several reasons. PUR scaffolds can be easily adapted to be injectable making 
clinical use easier and requiring no additional fabrication equipment [168, 169].  After injection, 
PURs react in situ to form a biocompatible and biodegradable tissue scaffold with inter-connected 
pores that effectively serves as a template for cell influx and tissue formation and remodeling [24].  
The mechanism of degradation includes hydrolytic degradation (on the order of months) and 
macrophage-mediated oxidative degradation by reactive oxygen species (ROS) secretion (on the 
order of weeks) that is ideal for the timescale of wound healing [25].  Finally, PUR has been shown 
to deliver biologics efficiently, typically delivering as much as 80% of the payload [24, 165, 166].  
However, a previous study has reported that 50-m PLGA microspheres with rhPDGF bound to 
the surface supported <10% release over 21 days, suggesting that primary amines in the protein 
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reacted with the polyisocyanate, resulting in loss of activity [24].  The present study has confirmed 
for the first time that nanoparticulate carriers incorporated in reactive PUR scaffolds support high-
efficiency, diffusion-controlled release as seen in Fig. 3.5.  The release data demonstrates 
cumulative release of si-NPs approaching 80% over 21 days compared to naked siRNA which 
was released rapidly, approaching 100% delivery of the payload in three days.  The mechanism 
of release for both free siRNA and si-NPs was found to be diffusion-controlled based on the 
Weibull model.  Further, scaling analysis with the Stokes-Einstein and Higuchi equations 
demonstrated that the initial release rates of siRNA and si-NPs scales appropriated to the 
hydrodynamic diameter of the solute. The diffusion-based release suggests that an additional 
level of control exists by altering si-NP diffusivity in the PUR matrix to tune the rate of release by 
varying the nanoparticle size. 
It is hypothesized that, in many applications, sustained delivery of siRNA into tissue 
defects will be ideal for producing a therapeutic effect since siRNA produces relatively transient 
gene silencing activity [259]. It is hypothesized that when the formulation tested here is translated 
in vivo, the initial burst release will establish gene silencing while the continual, slower siRNA 
delivery over the next few weeks will sustain the initial effect over a few weeks.  Importantly, 
several approaches exist for tuning PUR-based drug delivery to be more rapid or more sustained 
[165].  
Fig. 3.6A demonstrates that the activity of released NPs is not significantly reduced over 
the time frames tested (0-24, 24-48, 48-96 hours).  Sustained delivery of active complexes is 
critical to compensate for transiency of siRNA in a highly proliferative environment (i.e. tissue 
regeneration). Fig. 3.6B demonstrates that the siRNA-mediated reduction in GAPDH of PUR-
released si-NPs is dose dependent.   However, it is evident that there is partial loss of bioactivity 
post-release from the scaffold compared to fresh si-NPs.  It is possible that this reduction in 
silencing is due to reorganization of the micelle structure or a partial si-NP aggregation during 
lyophilization and incorporation into the PUR. There was a detectable difference in size revealed 
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by TEM and DLS (Fig. 3.2) of fresh micelles versus PUR-
of PUR-relesate si-NPs was also found to be reduced.  It could also be possible that unreacted 
components in the PUR specifically adsorb to the surface of the released si-NPs, thereby reducing 
the -potential of the si-NPs resulting in aggregation. Our unpublished data have shown that 1-
2% of the PUR mass leaches from the reactive material during the first 45 minutes of cure when 
incubated in serum medium.  The primary components in the leachates include polyester triol, 
dipropylene glycol, and triethylene diamine.  Hydrolytic degradation of the cured scaffolds 
releases α-hydroxy acids [25], which could bind electrostatically to the positive surface of the si-
NPs.  However, further studies will be necessary to better understand and overcome the alteration 
of the si-NPs during processing, and excipients such as agarose and sucrose may provide one 
route for improving their stability during lyophilization [260]. 
 
3.5. Conclusions 
Injectable poly(ester urethane) foams were successfully utilized for sustained release of bioactive 
si-NPs for an extended period of 21 days.  The si-NPs synthesized using RAFT were found to 
remain intact and bioactive following incorporation into and release from PUR scaffolds, although 
changes in si-NP size and bioactivity were evident relative to fresh si-NPs.  As a platform 
technology, the combination of PUR scaffolds and pH-responsive micellar siRNA carriers 
provides a logical approach to basic scientific studies of long-term siRNA-mediated gene silencing 
at local, pathological or healing tissue sites.  The described system also has the potential to be 
applied to control cell phenotype and fate in tissue constructs developed in vitro.  Finally, as a 
therapeutic, the described approach may be applied to reduce expression of deleterious genes 
and improve regeneration in tissue defects.   
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Chapter 4 
Aim 2 – In vivo development of siRNA platform 
Aim 3 – Silencing of PHD2 Promotes Angiogenesis in Vivo 
Text for Chapter 4 taken from: 
Nelson CE, Kim AJ, Adolph EJ, Gupta MK, Yu F, Hocking KM, Davidson JM, Guelcher 
SA, Duvall CL. Tunable Delivery of siRNA from a Biodegradable Scaffold to Promote 
Angiogenesis in Vivo. Advanced Materials. Early View. DOI: 10.1002/adma.201303520 .  
 
4.1 Introduction 
Clinical translation of siRNA-based therapies has been hampered by delivery barriers, 
including siRNA susceptibility to nuclease degradation, cell and endosomal membrane 
impermeability, and inability to achieve sufficient and sustained bioactivity at the target site [230, 
261].  Numerous nanotechnological and medicinal chemistry strategies have been tested to 
enhance the pharmaceutical properties of siRNA [27], and most of the recent focus has been on 
delivery of siRNA for cancer and liver targets, with the latter motivated by the fact that many 
intravenously-administered nanoparticles nonspecifically biodistribute to the liver.  Tremendous 
progress has been made toward systemic delivery applications, and promising clinical data has 
begun to appear [16, 262]. However, there is a significant, unmet need for clinically-translatable 
platform technologies that enable controlled and efficient in vivo delivery of small interfering RNA 
(siRNA) to therapeutically silence expression of disease-related genes [12]. The use of siRNA-
based strategies in regenerative medicine and tissue engineering is a relatively understudied but 
promising application of RNA interference (RNAi).  Topical delivery has been pursued clinically: 
for example, delivery to the eye for macular degeneration [226], to the lung for RSV [14], and to 
the skin for pachyonychia congenita [227].  A primary limitation to topical delivery for regenerative 
applications is that siRNA has a relatively short half-life, especially in rapidly dividing cells (i.e., 
representative of regenerating tissue), where the maximum silencing effect has been noted to be 
at two days post-transfection [17], with gene silencing bioactivity being exhausted by one week 
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[18].  In one successful approach, agarose hydrogels containing siRNA packaged with 
Lipofectamine 2000 was found to produce potent siRNA silencing in vivo.  However, this 
commercial transfection reagent is optimized for in vitro use, and rapid diffusion out of the 
hydrogel or loss of activity of the lipoplexes necessitates multiple applications [21, 22, 171].  Other 
natural biomaterials such as alginate, collagen, and agarose have also been applied as depots 
for local delivery of siRNA [19, 20]. Other hydrogel and microparticle depots have been developed 
to achieve sustained, local delivery of siRNA intratumorally and at sites of inflammation [170, 173, 
175, 191], though none of these applications provided controlled siRNA delivery from a 
biomaterial scaffold that promoted host cell infiltration and tissue regeneration.  
More recently, biodegradable, synthetic scaffolds developed toward applications in 
regenerative medicine have demonstrated controlled and sustained siRNA delivery in vitro (i.e., 
ranging 20-50 days of release in vitro), including prefabricated ε-caprolactone and ethyl ethylene 
phosphate copolymer (PCLEEP) nanofibers [193], poly(lactic-co-glycolic acid) (PLGA) nanofibers 
[194], and our porous polyester urethane (PEUR) scaffold design [181].  These classes of porous 
tissue scaffolds have the advantages of being easily tunable and of being adaptable for filling 
critically-sized defects with biodegradable templates that promote new tissue in-growth.  PEUR 
scaffolds have been shown to promote regeneration in both excisional cutaneous wounds and 
bone defects and have desirable properties, including the potential for injectable delivery of 
components that form a porous scaffold in situ, degradability into biocompatible products at rates 
dictated by the composition of the polyester triol and the isocyanate, and controlled release of 
growth factors and other therapeutic agents [24, 25, 165, 177, 178, 263]. We recently adopted 
PEUR scaffolds for delivery of siRNA-loaded polymeric nanoparticles [181], and the current report 
showcases the ability of this platform to achieve a high level of gene silencing efficiency and 
tunability in vivo, along with a proof of concept application of this delivery platform for 
enhancement of angiogenesis within tissue defects. 
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4.2 Results and Discussion 
Polymeric nanoparticles with pH-dependent endosomal escape behavior have been 
shown to enhance siRNA intracellular bioavailability [23, 124, 264]. To leverage this efficient 
delivery approach, siRNA loaded nanoparticles were made from the diblock copolymer 
poly[DMAEMA71-b-(BMA103-co-PAA68-co-DMAEMA57)] (Fig. 4.1A, Mn=43kDA, PDI = 1.41), which 
was synthesized using reversible addition-fragmentation chain transfer (RAFT). RAFT is a 
controlled radical polymerization technique amenable to biomedical applications because it 
enables synthesis of monodisperse and well-defined polymers with block or other architectures 
and telechelic end chemistries that provide opportunities for site-specific bioconjugation [241, 242, 
248, 265]. Poly[DMAEMA71-b-(BMA103-co-PAA68-co-DMAEMA57)] was self-assembled into siRNA 
loaded micellar NPs (si-NPs, Dh = 39.6±12.6 nm, ζ-potential = +20.2 mV) that had been optimized 
for pH-dependent membrane disruption tuned for endo-lysosomal escape [23, 133] (Appendix 
Fig. A6).  Trehalose (0, 1.25, 2.5, 5 wt% of PEUR denoted as 0T, 1.25T, 2.5T, and 5T 
respectively) was added to samples of si-NPs to optimize the stability through lyophilization [266] 
and to act as a porogen in the cured PEUR scaffolds. Lyophilized si-NPs samples with varied 
quantities of trehalose were resuspended into polyester triol prepolymers (Fig. 4.1B) and 
fabricated into scaffolds through a reactive foaming process with lysine triisocyanate (LTI) or 
hexamethylene diisocyanate trimer (HDIt) (Fig. 4.1C).  
The scaffolds were then incubated in PBS to trigger diffusion of si-NPs from the PEURs 
in order to assess the physicochemical properties and bioactivity of the released si-NPs.  Analysis 
of the supernatants revealed that si-NPs released from the PEUR scaffolds were similar to freshly-
made si-NP samples in terms of size and ζ-potential, suggesting that no aggregation or 
destabilization occurred during scaffold formation (Fig. 4.1D).  Confocal microscopy of mouse 
embryo fibroblasts (NIH3T3s) treated with scaffold-released si-NPs with cy5.5-labeled siRNA 
demonstrated that there was a similar level of uptake and intracellular staining pattern relative to 
NIH3T3s treated with an equivalent concentration of freshly prepared si-NPs (Fig. 4.1E).   
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Likewise, the gene silencing dose response from scaffold-released si-NPs loaded with 
siRNA against the model gene peptidylpropyl isomerase B (PPIB) was statistically equivalent to 
that achieved with freshly made si-NPs (Fig. 4.1F).  Addition of the excipient trehalose and 
preparation/lyophilization of si-NPs in dH2O rather than salt-containing PBS prior to incorporation 
into PEUR scaffolds improved stability of the si-NPs during scaffold fabrication.  Stabilization of 
si-NP physicochemical properties was also functionally significant in terms of bioactivity and 
resulted in improved bioactivity relative to our previous in vitro studies where the released si-NPs 
(lyophilized in salt-containing PBS) were larger in size, had lower ζ-potential, and suffered from a 
33% reduction in gene silencing relative to freshly made si-NPs (Fig. 4.1D) [181].  
PEUR scaffolds were next cured as cylinders containing si-NPs loaded with FAM-labeled 
23-mer double stranded DNAs (a model for siRNA) and 0, 1.25, 2.5, and 5 wt% trehalose relative 
to the mass of the polyurethane precursors.  SEM imaging of the scaffolds demonstrated 
interconnected pores necessary for si-NP release and cell infiltration (Fig. 4.1 G-J), and confocal 
microscopy revealed homogenous loading of the si-NPs throughout the scaffolds (Fig. 4.1K-N).  
The kinetics of si-NP release from the scaffolds were monitored using fluorescence. The rate of 
si-NP release was dependent on the quantity of trehalose in the scaffold (Fig. 4.1O).  Trehalose 
can act as a stabilizer and a porogen [267], and with this system, the release rate of the si-NPs 
correlated to the quantity of trehalose present. Trehalose is hydrophilic and microdomains of 
trehalose rapidly dissolve upon exposure to water creating microchannels that accelerate NP 
diffusion through the scaffold. The effects of the isocyanate chemistry were also assessed, and 
the si-NP release rate was measured with PEUR scaffolds made from both LTI and HDIt, the 
latter being more hydrophobic and is known to degrade more slowly [25, 169]. For in vitro tests, 
the diffusivity of the si-NPs was lower in the PEUR scaffolds made with HDIt than LTI scaffolds. 
This property increased the versatility and provided an additional level of control for this system 
for in vitro siRNA delivery (Fig 4.1P). Modeling with the Weibull function [247] showed that the 
release mechanism could be characterized as diffusion-controlled in all cases (Appendix Table 
A2 and A3). 
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Fig 4.1 Material synthesis and characterization of the PEUR scaffold si-NP delivery platform. A) The 
structure of the diblock copolymer developed previously[30] contains an siRNA condensing block composed 
of DMAEMA and a pH-responsive block composed of a copolymer of DMAEMA, BMA, and PAA. B) The 
polyester alcohol (polyol or triol) that was used in the synthesis of polyurethanes were composed of 
copolymers of poly(ε-caprolactone), poly(glycolide), and poly(D,L-lactide). C) Isocyanate-containing 
crosslinking components used for PEUR formation included hexamethylene diisocyanate trimer (HDIt) and 
lysine triisocyanate (LTI). D) The excipient trehalose stabilized the size and ζ-potential of released si-NPs 
compared to si-NPs prepared in PBS.  E) PEUR scaffold-released si-NPs deliver siRNA into the cytoplasm 
of cells in vitro similar to freshly prepared si-NPs (scale = 30µm). F) Gene silencing activity was similar in 
PEUR scaffold-released si-NPs compared to freshly-made si-NPs as revealed by RT-PCR IC50 analysis of 
target gene expression (p=NS). G-J) SEM images of PEUR scaffolds (LTI-based materials shown) 
containing varying weight% of trehalose (5% by weight is 5T) demonstrate the porous scaffold architecture 
(Scale = 300µm). K-N) Maximum intensity projections from confocal microscopy showed homogenous 
loading of si-NPs into the scaffold (note dark areas correspond to pores, scale = 300µm). O-P) Temporal 
release profile of si-NPs from PEUR scaffolds in vitro demonstrated diffusion controlled release 
(characterized by Weibull model) that could be modulated through varying the concentration of trehalose 
or alteration of the isocyanate chemistry.  Q-R) The rate of release of si-NPs in vivo was increased relative 
to the release in vitro but was also tunable based on varying the concentration of the excipient trehalose. 
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To measure release kinetics in vivo, PEUR scaffolds were synthesized containing si-NPs 
made with cy5-labeled siRNA (description in Appendix B). The scaffolds were implanted 
subcutaneously in balb/c mice, and the temporal release profile was characterized in vivo through 
fluorescence imaging with an IVIS200®. Release of si-NPs from the PEUR scaffolds was faster 
in vivo relative to in vitro (Fig. 4.1Q-R, images in Appendix Fig. A7), which may be attributable 
to both increased mechanical forces and cell-mediated effects on the scaffold (i.e. oxidative 
degradation) [25]. Similar to the in vitro studies, the in vivo release kinetics were tunable based 
on the quantity of trehalose added, and the release mechanism was found to be diffusion-
controlled based on the Weibull model (Fig. 4.1O-R, black line).  Table 4.1 reports the time that 
it took for each formulation tested to release 50, 60, or 75% of the total payload in vivo. ANOVA 
analysis showed that isocyanate chemistry was a significant predictor of release kinetics when 
this variable was tested across all of the scaffold formulations (p<0.05). This analysis suggests 
that the through the right combination of isocyanate and trehalose concentration, a variety of 
release profiles are available, which provides a significant advantage for in vivo applications.  
Relatively long-term release has been achieved in vivo using biodegradable hydrogel depots [174] 
but no previous platform has demonstrated locally-sustained siRNA release for several weeks 
and an ability to finely tune the release kinetics in vivo from a tissue scaffold that promotes cell 
infiltration and regeneration.  Reports on regenerative scaffolds including PCLEEP nanofibers, 
PLGA nanofibers, and porous PEUR have been applied to achieve sustained release in vitro [181, 
193, 194], but tunability and in vivo validation were not achieved.  The current platform provides 
the unique capability to match siRNA delivery to the time course of expression of a target gene 
and to tune the system so that siRNA release, scaffold degradation, and cell/tissue infiltration can 
be temporally aligned in order to optimize tissue regeneration.  
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Table 4.1 Days of release required for 50%, 60%, and 75% release to be reached 
Group Formulation 50% (days ± SE) 60% (days ± SE) 75% (days ± SE) 
1 LTI – 0T 4.67 (±1.46)4,6 10.57 (±2.94) 4,6 45.27[a] 
2 LTI – 1.25T 2.89 (±0.37)4,6 5.41 (±4.97)4 7.73(±6.86)3 
3 LTI – 5T 0.07[a] 0.21[a] 1.16(±0.31)2,5,6 
4 HDIT – 0T 10.09(±5.17)1,2,5,6 20.86(±2.81) 1,2,5,6 61.27[a] 
5 HDIT – 1.25T 2.90(±1.32)4 6.16(±2.31) 4 18.83(±7.49)3 
6 HDIT - 5T 0.52(±0.17)1,2,4 1.21(±0.13) 1,4 4.30(±1.83)5 
[a] Extrapolated from Weibull model [b] Superscripts denote significance (p<.05) to the designated group 
 
Dicer substrate siRNA (DsiRNA, see description with Appendix Table A1) designed 
against the model gene PPIB was used to form si-NPs that were incorporated into PEUR scaffolds 
made with the “slow” release LTI formulation (0T in Fig 4.1O). The PPIB si-NPs efficiently reduced 
target gene expression within the subcutaneously implanted scaffolds, with 82%, 95%, 83% gene 
silencing achieved at days 5, 12, and 21, respectively (Fig 4.2A). Importantly, PEUR scaffolds 
loaded with si-NPs containing a scrambled sequence of DsiRNA showed no significant gene 
silencing at any time point relative to control scaffolds containing no si-NPs. This remarkable gene 
silencing was achieved with a relatively low dose of 200 g DsiRNA/kg of mouse (300 pmol total 
dose). Next, the dose response behavior using this 0T LTI PEUR scaffold was thoroughly 
characterized at day 12. This study revealed a low IC50 of 41.8 µg/kg (mass siRNA / mass mouse; 
total dose of 62.7 pmol, Fig 4.2B) calculated from a 4-parameter model (Appendix Equation 
A2). The potency and sustained action of siRNA with this system compares favorably with  other 
recent regenerative applications of siRNA in vivo, for example, agarose depots loaded with 20 
pmol siRNA achieved 76% knockdown of the target gene p53 at day 10, but this required 2 
repeated applications and use of the commercial transfection reagent Lipofectamine 2000 to 
improve cell uptake [21]. Tissue regenerative siRNA delivery applications in vivo using synthetic 
biomaterials are limited, but a recent report using poly-D,L-lactic acid-p-dioxanone-polyethylene 
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glycol block co-polymer (PLA-
DX-PEG) pellets implanted into 
mouse dorsal muscle pouches 
served as a depot for the 
delivery of relatively high doses 
of 10 - 30 nmol siRNA per site 
and achieved ~75% gene 
silencing at day 1 that was 
sustained for 7 days, with ~50% 
silencing at day 7 [192].  The 
current scaffold based 
approach provided longer-term 
gene silencing with a 100-fold 
lower siRNA dose, while also 
providing a porous template 
that promotes tissue 
regeneration.   
Next, the correlation between si-NP release kinetics and the resulting time course of gene 
silencing was tested.  For the LTI-based PEUR scaffolds, the fast releasing 5T formulation 
resulted in 94% PPIB silencing at day 5, compared to 80% for the slower release 0T scaffolds 
(p<0.005).  However, the faster releasing 5T scaffolds had a more transient gene silencing effect 
and produced 45% PPIB silencing at day 35 compared to the slower releasing 0T scaffolds which 
produced 90% silencing at 35 days (p<0.0005). A similar analysis was performed for HDIT as 
reported in Appendix Fig. A8, and the results showed a similar correlation between si-NP release 
kinetics and the temporal gene silencing profile.  To further validate our measurements, 
Fig 4.2 The si-NP-loaded PEUR scaffolds provide a potent and 
temporally-tunable gene silencing platform. A) PPIB mRNA 
was significantly silenced by siRNA-NP-PEUR at day 5, 12, and 21 
(p<0.002 for all groups, n=4) in subcutaneous implants in mice at 
a siRNA dose of 200µg/kg. B) A dose response at day 12 
demonstrated a low IC50 for siRNA-NP-PEUR of 41.8 µg/kg C) 
The temporal gene silencing profile was tuned through the use of 
trehalose to control release kinetics (day 5 p<.0005 0T vs 5T, day 
35 p<.0005 0T vs 5T). D) Western blotting for PPIB at day 12 
showed significant protein reduction in PPIB siRNA loaded 
scaffolds (n=3, p<.05). E) A longitudinal study demonstrated 
significant luciferase reduction over the time course of wound 
healing, highlighted in gray, in a COL1A2 luciferase reporter 
mouse model (p<.01, n=5). 
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knockdown of PPIB protein from scaffold explants at day 12 was evaluated (200 g DsiRNA/kg 
mouse, 0T/LTI).  As shown in the western blot in the inset (Fig. 4.2E) approximately 75% less 
PPIB protein was detected (p<0.05). The combination of low dose, sustained silencing effect, and 
tunability achieved here is unprecedented for in vivo delivery of siRNA from a regenerative tissue 
scaffold.  The potency of our system may have been enhanced by direct, substrate-mediated 
transfection of si-NPs into cells migrating into the cell-inductive PEUR scaffold. For example, high 
local concentration of plasmid DNA, achieved through immobilization onto the surface of 
materials, has been shown to increase transfection efficiency 10-100 fold relative to plasmid 
polyplexes freely diffusing within the cell’s surroundings [182-184].  This uptake mechanism 
mimics the pathway hijacked by viruses that attach to extracellular matrix proteins to enhance 
their rate of cellular internalization [185, 186]. 
Transgenic mice with a collagen α-2(I) chain (COL1A2) luciferase reporter were next 
utilized to assess the ability of the si-NP-PEUR platform to effectively silence a wound-related 
gene throughout the entire time course of healing.  The COL1A2 reporter is upregulated between 
approximately days 7-14 in mouse incisional and laser irradiated wounds [268, 269]. A COL1A2 
luciferase reporter mouse model was used to allow a longitudinal, quantitative, and protein-level 
readout of luciferase silencing using intravital bioluminescence imaging. The mice received 
subcutaneously-implanted PEUR scaffolds (OT, LTI) containing si-NPs loaded with DsiRNA 
against luciferase or a scrambled control sequence.  In the control animals, the activity of the 
COL1A2 reporter was elevated between approximately days 8-20 post-wounding (highlighted in 
gray) (Fig. 4.2D). However, incorporation of luciferase DsiRNA maintained the local luciferase 
activity at approximately baseline levels, and there was a significant reduction in luciferase activity 
in these scaffolds relative to scaffolds containing si-NPs loaded with scrambled siRNA (p<0.01, 
n=4). The efficient and sustained gene silencing achieved throughout the full time course of 
wound healing suggests that this platform can be utilized to abrogate the function of a therapeutic 
target gene throughout the healing process. 
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To exclude a nonspecific biological response to the si-NPs, histology of tissue explants 
and PCR against signal transducer and activator of transcription factor 1 (STAT-1, a readout for 
TLR activation [270]) and tumor necrosis factor α (TNFα) was performed. Histology revealed that 
there was no inflammation or toxicity associated with incorporation of the si-NPs into the PEUR 
scaffolds (Appendix Fig. A9), and PCR for STAT-1 and TNFα showed that the si-NPs did not 
increase these inflammatory markers relative to empty scaffolds (Appendix Fig. A10).  
Prolyl hydroxylase 2 (PHD2) activity triggers degradation of the pro-angiogenic 
transcription factor hypoxia inducible factor 1α (HIF1α) during normoxia. When PHD2 is naturally 
inactivated (i.e., under hypoxic conditions) or silenced through RNAi, HIF1α mediates 
transcription of pro-angiogenic genes such as vascular endothelial growth factor (VEGF), 
fibroblast growth factor 2 (FGF-2), and others [271]. To demonstrate the therapeutic potential of 
our platform for promoting tissue regeneration, si-NPs were formulated with PHD2 DsiRNA 
(PHD2-NPs or scrambled siRNA (SCR-NP) and incorporated into PEURs scaffolds that were 
implanted subcutaneously. At 14d, PCR revealed an ~80% reduction in PHD2 levels (Fig. 4.3A) 
which resulted in a ~200% increase in VEGF and ~300% increase in FGF-2 mRNA levels. For an 
evaluation of neovessel formation with the scaffolds, immunohistochemistry (IHC) for CD31 was 
done at 14d and 33d, and development of stable, functional vascular structures was imaged and 
quantified using micro-CT following systemic vascular perfusion with a contrast agent at 33d. 
CD31 IHC showed visually increased vessel density in PHD2-NP-containing scaffolds (Fig. 3B) 
and a significant, 280% increase in vessel area at day 33 (Fig. 4.3C-D). Scaffolds characterization 
with micro-CT provided quantitative histograms that demonstrated that PHD2-NPs increased both 
number and size of vessels within the scaffolds (Fig. 4.3E, representative images in Fig. 4.3F). 
Quantitative 3D image analysis [272] showed that PHD2-NPs increased the vascular volume by 
300% and increased the mean vascular thickness by 137% (Fig. 4.3G). These data convincingly 
demonstrate the regenerative potential of this platform, as formation of robust, mature vessels is 
one of the primary challenges in tissue regeneration.  We anticipate that sustained RNAi-induced 
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modulation of transcription factors, such as HIF1, that control groups of related genes has the 
potential to produce better-orchestrated and more robust effects on tissue regeneration compared 
to delivery of a single growth factor (e.g., VEGF of FGF), which is the current standard. For 
example, VEGF has had limited therapeutic success because it produces immature vessels that 
suffer from instability and poor long-term function [273].  
 
Fig 4.3. Sustained silencing of PHD2 increases angiogenesis within PEUR tissue scaffolds. A) 80% 
silencing of PHD2 increased VEGF and FGF-2 expression by 200% and 290% respectively (*p<0.01). B) 
CD31 staining was significantly increased within PHD2 scaffolds at day 14 and day 33 (Scale = 200 µm, 
vessels appear read, nuclei are counterstained purple with hematoxylin, and white space represents 
residual PEUR scaffold). C-D) CD31 sections were quantified showing a significant increase in vessel 
area at day 33 (*p<0.01). E) Micro-CT of explanted PHD2-NP scaffolds showed a significant increase in 
both vessel number and vessel size for PHD2-NP scaffolds as shown in the histogram. F) Micro-CT 
images visually demonstrate the increased vasculature within the scaffolds. G) Quantitative analysis of 
3D micro-CT vessel images revealed a significant increase in vascular volume and mean vascular 
thickness within PHD2-NP-loaded scaffolds. 
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4.3 Conclusions 
This study validates that si-NP delivery from tissue inductive PEUR scaffolds provides a 
new, tunable platform technology for efficient, local gene silencing. The in vitro and in vivo data 
suggest that this platform is highly versatile for siRNA delivery in vitro or in vivo through tuning 
the quantity of trehalose added during PEUR scaffold fabrication and by alteration of the chemistry 
of the isocyanate. This provides the opportunity to tune this delivery system based on the desired 
expression profile of the therapeutically targeted gene or to optimally match rates of scaffold 
degradation, tissue growth, and siRNA delivery. PHD2 silencing studies demonstrated that this 
platform can promote angiogenesis in vivo.  These proof-of-concept data validate that this 
platform provides a powerful research tool and also represents a technology with the potential to 
be utilized therapeutically for manipulation of genes whose silencing promotes tissue 
regeneration. 
 
4.4 Experimental Section  
si-NP synthesis and characterization 
Dicer substrate siRNAs (DsiRNAs) were obtained from IDT and screened in vitro for activity 
before use in vivo. A diblock copolymer composed of 2-(dimethylamino)ethyl methacylate 
(DMAEMA), 2-propylacrylic acid (PAA), and butyl methacrylate (BMA) was synthesized using 
reversible addition-fragmentation chain transfer (RAFT) polymerization as described previously 
[23, 181]. NPs were fabricated by dissolving in ethanol, followed by slow addition of dH2O, which 
spontaneously triggered formation of micelles.  Subsequently, siRNA was electrostatically loaded 
onto the surface of NPs.  Dynamic light scattering (DLS, Zetasizer nano-ZS Malvern Instruments 
Ltd, Worcestershire, U.K.) was used to analyze size and zeta potential of the si-NPs.   
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si-NP-PEUR synthesis and characterization 
The polymeric NPs (1mg) were mixed with siRNA (5 nmol, 0.08mg) in an RNAse free 
polypropylene tube and allowed to electrostatically condense for 30min. Trehalose was added to 
the si-NPs at varying concentrations from 0 to 5 wt% of PEUR and allowed to stabilize for 30 min.  
The solutions were frozen and then lyophilized. Lyophilized si-NP samples were suspended into 
a 900 Da polyester triol with a backbone comprised of 60 wt% ɛ-caprolactone, 30 wt% glycolide, 
and 10 wt% D,L-lactide. PEUR scaffolds were synthesized by reacting 67 µmol of the polyol 
component of PEUR with a slight excess of lysine triisocyanate (LTI, 193 µmol, 35mg) in the 
presence of 67 µmol water. The water reacts with the isocyanate to produce CO2 and serves as 
a blowing agent that creates the pores within the scaffold. The polyol and LTI were mixed using 
a Hauschild DAC 150 FVZ-K SpeedMixer (FlackTek, Inc., Landrum, SC). Alternatively, 42 µmol 
of polyol was reacted with a slight excess of hexamethylene diisocyanate trimer (HDIt, 111 µmol) 
in the presence of 63 µmol of water.   
The resulting 100mg PEUR foams were sectioned into 6mm diameter x 1 mm thick discs 
and imaged with a fluorescent confocal microscope (Zeiss LSM 710 Meta Oberkochen, Germany) 
to analyze the distribution of fluorescently labeled si-NPs in the scaffold.  Scaffold morphology 
was assessed with a scanning electron microscope (SEM Hitachi S4200, Tokyo, Japan) for 
structure and porosity. PEUR scaffolds were immersed in PBS, and releasate was collected and 
quantified using fluorescence for percent release.  Released si-NPs were incubated on NIH3T3 
mouse embryo fibroblasts at varying concentrations that were imaged with a fluorescent confocal 
microscope (Zeiss LSM 710 Meta) and measured for gene silencing by RT-PCR. 
 
Subcutaneous Implant of si-NP-PEUR  
The animal studies were conducted with adherence to the guidelines for the care and use 
of laboratory animals of the National Institutes of Health (NIH). All experiments with animals were 
approved by Vanderbilt University’s Institutional Animal Care and Use Committee (IACUC).  Cy5-
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labled DsiRNA was complexed into NPs and loaded into PEUR scaffolds in the same quantities 
outlined above.  Scaffolds were sectioned into approximately 6 mm x 1mm discs and sterilized by 
ethylene oxide treatment. 8-10 week balb/c mice were purchased from Charles River 
Laboratories. The animals were fed a standard chow diet ad libitium and had free access to water. 
The mice were anesthetized with 1.5-2% isoflurane and maintained at 37°C. The mice abdomen 
was shaved and sterilized. A 1 cm incision was made in the ventral side of the skin in the abdomen 
of the mice. A pocket was made with sterilized haemostatic forceps on each side of the midline 
and 6 mm scaffolds were implanted subcutaneously. The incision was sutured, and the mice were 
allowed to recover at 37°C. Analgesic agent (ketoprofen, 5 mg/kg) was injected as needed. 
 
In vivo release kinetics 
Release of si-NPs from the scaffold was quantified by measuring the loss of Cy5 
fluorescence over time in regions of interest (ROIs) defined by the PEUR implant using an IVIS 
200® imaging system (Caliper Life Sciences, Hopkinton, Massachusetts).  Mice were 
anesthetized with 1.5-2% isoflurane and maintained at 37°C and measured with constant image 
settings every 2-3 days.  
 
In vivo gene silencing  
siRNA against cyclophilin B (PPIB) was formulated into si-NPs, incorporated into PEUR 
scaffolds, and implanted subcutaneously for 5, 12, 21, or 35 days using the procedure described 
above. At defined endpoints, the mice were anesthetized heavily with isoflurane and sacrificed by 
cervical dislocation. The scaffolds were collected postmortem and bisected in half for preparation 
for both histology and PCR. RNA was extracted with TRIZOL (Invitrogen, Carlsbad, CA) and 
purified with RNEasy spin column (Qiagen, Venlo, Netherlands).  The expression of PPIB was 
evaluated by RT-PCR using the ΔΔCt method normalizing to GAPDH.  Histological sections were 
used to evaluate the host response to the implants through H&E staining. RT-PCR for 
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inflammatory markers was also performed to evaluate immune response and activation of toll like 
receptor signaling. A western blot was used to confirm protein level silencing using primary 
antibodies anti-PPIB (Sigma) and anti-B-actin (Santa Cruz Biotechnology).  The full method is 
described in Appendix B.  
 
In vivo gene silencing during the time course of wound healing 
For a longitudinal, protein level readout, firefly luciferase siRNA was formulated into si-
NPs, incorporated into PEUR scaffolds, and implanted into transgenic balb/c mice with a COL1A2 
luciferase reporter using the same procedure described above. The bioluminescence at the 
scaffold site was evaluated every 2 days for 24 days using an IVIS® 100 bioluminescence imaging 
system. 
 
In vivo silencing of PHD2 
 PHD2 or scrambled siRNA was formulated into si-NPs that were incorporated into PEUR 
scaffolds and implanted subcutaneously into balb/c mice. Mice were sacrificed at day 14 and 
scaffolds were evaluated for gene expression by real-time RT-PCR.  At day 33, scaffold 
vascularization was assessed with microCT using established methods [272, 274-276] (full 
method can be found in Appendix B). H&E staining and CD31 immunohistochemistry were done 
on scaffolds explanted at days 14 and 33.  
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Chapter 5 
Aim 4 – Development of a systemic carrier for siRNA 
Text for Chapter 5 taken from: 
Nelson CE‡, Kintzing JR‡, Hanna A, Shannon JM, Gupta MK, Duvall CL. Balancing 
Cationic and Hydrophobic Content of PEGylated siRNA Polyplexes Enhances Endosome 
Escape, Stability, Blood Circulation Time and Bioactivity in Vivo. ACS Nano. 2013, 7(10): 
8870-8880.  
‡ Equally Contributing Authors 
5.1 Introduction 
Small interfering RNA (siRNA) is emerging as a therapeutic approach for potent, gene-
specific silencing [12], but clinical use of siRNA hinges on the development of safe and effective 
delivery technologies [230]. A variety of cationic biomaterials have been developed for siRNA 
packaging and delivery including polymers, lipids, polysacaccharides, cell penetrating and 
fusogenic peptides, and dendrimers [27, 67]. Cationic vehicles are effective for in vitro delivery 
because they condense siRNA into nano-sized complexes with positive surface charge that 
promotes endocytosis by electrostatically adsorbing onto anionic cell membranes [277]. However, 
intravenous administration of cationic lipoplexes or polyplexes, which is desirable for many 
therapeutic applications, often results in particle instability and nonspecific interactions with blood 
components that induce opsonization, aggregation of red blood cells, platelet activation, 
excessive biodistribution to the lungs, and, in extreme cases, rapid mortality [136-139]. 
Polyethylene glycol (PEG) has been used extensively to improve the biocompatibility of 
drug delivery nanoparticles and tissue engineered hydrogels. Functionalization of the exterior of 
drug delivery nanocarriers with PEG blocks adsorption of proteins, inhibits hemolysis or 
aggregation of erythrocytes, avoids immune stimulation, improves circulation time, protects the 
cargo from enzymatic degradation, and generally provides colloidal stability and ‘stealth’ [278-
283].  PEGylation of cationic carriers has been successfully utilized to endow these properties 
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onto common polycations such as polyethylenimine (PEI), poly-L-lysine, polyamidoamine 
(PAMAM) and poly(propylene imine) (PPI) dendrimers, and poly(N,N-Dimethylaminoethyl 
methacrylate) (PDMAEMA) [146-150]. 
Poly(EG-b-DMAEMA) (PEG-DMAEMA) demonstrates efficient siRNA packaging and 
relatively low cytotoxicity [150], and studies on the effects of PEG architecture have shown that 
performance of a PEG-DMAEMA diblock structure is superior to brush or copolymer architectures 
[280]. PDMAEMA, like PEI, is believed to operate through the proton sponge effect for endosomal 
escape.[284, 285] However, it has been found that active, pH-dependent membrane disruptive 
mechanisms improve intracellular bioactivity relative to pure proton sponge [286]. Recently, it has 
been shown that copolymerization of the hydrophobic monomer butyl methacrylate (BMA) with 
DMAEMA, DEAMA, or DMAEMA and propyl acrylic acid (PAA) in a core-forming block [132, 248] 
could be used to tune the pH-dependent membrane disruptive behavior of micelleplexes; these 
micelleplexes were designed to be pre-assembled and nucleic acids were subsequently 
condensed onto coronas consisting of homopolymer blocks of DMAEMA [133, 287, 288]. 
Hydrophobic modification has also been found to have other beneficial effects on cationic 
delivery systems including serum stability, membrane binding, improved dissociation in the 
cytoplasm, and decreased cytotoxicity [289]. Recently, a self-assembled micelleplex made from 
a triblock polymer poly(EG-b-nBA-b-DMAEMA) that packaged siRNA in the corona was found to 
have improved gene silencing in vitro and had increased tumor uptake relative to poly(EG-b-
DMAEMA)-based polyplexes [290].  While polymer blocks of DMEAMA with nBA are beneficial 
for stability, they do not generate polymers with active, pH-dependent membrane disruption 
behavior, possibly reducing the gene silencing activity due to endosomal entrapment.  The 
polymers are also-pre-assembled and condense siRNA onto the positively charged micelle 
corona that contains a mixture of PDMAEMA and PEG. Though it wasn’t reported, this also 
presumably resulted in micelleplexes with a positive zeta potential, which would hinder in vivo 
circulation time and performance [291, 292].  
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In this work, a novel series of copolymers of DMAEMA and BMA, ranging from 0-75 mol% 
BMA, were synthesized using a simple, one pot RAFT polymerization reaction from a PEGylated 
macro-chain transfer agent (macro-CTA).  This polymer series was designed for core-
complexation of siRNA into PEG-corona polyplex nanoparticles (NPs) whose assembly is 
electrostatically-triggered upon simple mixing with siRNA in buffer of appropriate pH. This strategy 
enables formulation of surface charge neutral siRNA-loaded NPs core-stabilized by a combination 
of electrostatic and hydrophobic interactions.  The balance of cationic and hydrophobic content in 
the poly(DMAEMA-co-BMA) NP core-forming block was carefully titrated in order to identify 
improved PEGylated polycation variants that are optimized for in vivo performance based on a 
combination of improved stability and inertness in the blood circulation and pH-dependent 
membrane disruptive behavior finely-tuned for efficient endosomal escape and cytoplasmic 
delivery.  The performance of polyplexes made from PEG-(DMAEMA-co-BMA) polymers with 
varied quantities of BMA were benchmarked against the standardized and previously-optimized 
PEG-DMAEMA diblock architecture [150].  
 
5.2 Results and Discussion 
Fig. 5.1 Polymer synthesis scheme for PEG-(DMAEMA-co-BMA). 
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Polymer Synthesis and Characterization 
A series of pH-responsive diblock copolymers were synthesized from a PEG5K macro-CTA 
using RAFT polymerization (Fig. 5.1). Six polymers were synthesized with varied copolymer ratios 
of DMAEMA and BMA in the second 
block ranging from 0-75% BMA by 
adjusting the composition in the feed 
(Table 5.1). The synthesis was 
completed by the RAFT 
polymerization technique, which has 
numerous advantages including 
formation of monodisperse polymers 
[241, 242] as obtained here (all Mw/Mn < 1.1). Additionally, the single step polymerization was a 
facile and scalable synthesis that yielded easily-purified polymers with composition and molecular 
weight that closely matched the targeted values. This polymer series was designed to overcome 
the challenges related to systemic intravenous administration of polyplex nanoparticles with highly 
cationic surfaces [137-139].  It was posited that polyplex NPs comprising a PEG shell and a 
poly(DMAEMA-co-BMA) core will produce optimal properties for navigating both systemic 
circulation and intracellular (i.e., endosomal) delivery barriers following intravenous delivery. 
 
Characterization of pH-dependent Polymer Micelle Assembly and Disassembly in Absence of 
siRNA 
In order to identify optimal formulation conditions for efficient siRNA packaging, DLS was 
used to assess the pH-dependent micelle assembly/disassembly behavior of the polymers across 
a range of pHs, from 7.4 to 4.0.  As expected, the relative acidity required to trigger polymer 
micelle disassembly was directly related to the %BMA content in the poly(DMAEMA-co-BMA) 
block. The 0B and 25B polymers did not spontaneously form micelles at any pH tested, while 
Table 5.1 Molecular weight and percent composition of 
the polymer library 
Polymer Name 
(%BMA in feed) 
Mn(g/mol) PDI %BMA %DMAEMA 
0B 17035 1.092 0.0 100.0 
25B 18747 1.075 23.8 76.2 
40B 20765 1.117 39.6 60.4 
50B 18040 1.040 48.3 51.7 
60B 19938 1.081 58.6 41.4 
75B 17349 1.053 74.5 25.5 
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polymers with 50% or more BMA content formed micelles (~25nm diameter, Fig. 5.2) at pH 7.4, 
with the 40B polymer appearing to be in a transition state at this pH.  The 40B, 50B, and 60B 
polymeric micelles dissociated as the pH was lowered, and the pH where this transition occurred 
was inversely proportional to the %BMA in the polymer (Fig. 5.2C-E, Fig. 5.2D inset TEM images 
visually confirmed NP assembly for 50B at pH 7.4). The 75B polymer remained in stable micellar 
state at all pHs tested, suggesting that it did not accumulate sufficient cationic charge, even at pH 
4.0, to destabilize the increased hydrophobic interactions between BMA (Fig. 5.2F).   
 
Fig. 5.2 DLS measurements characterizing pH-dependent assembly/disassembly behavior of PEG-
(DMAEMA-co-BMA)] polymers. DLS at varying pH values for polymers with A) 0% BMA, B) 25%BMA, C) 
40%BMA, D) 50%BMA, E) 60% BMA, F) 75% BMA. DLS data are shown for decreasing pH values down 
to pH 4.0 or until full NP disassembly occurred. Polymer 50B demonstrated the most dynamic pH-
dependent behavior over the physiologically-relevant range tested. The inset TEM of 50B polymer at pH 
7.4 shows spherical nanoparticles (scale bar = 100nm) 
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When the polymers are “pre-assembled” into micelles, the cationic poly(DMAEMA-co-
BMA) polymer block is located in the particle core and is not readily accessible to electrostatically 
bind to siRNA.  As a result, the polymers with a higher mole % of BMA in the poly(DMAEMA-co-
BMA) block must be dissolved in a more acidic buffer to ensure that the DMAEMA tertiary amines 
are highly protonated, causing the polymers to exist as solubilized unimers due to electrostatic 
repulsion between poly(DMAEMA-co-BMA) blocks.  In this unimeric state, the cationic polymer 
segments are fully exposed, and mixing with siRNA triggers electrostatic interactions that drive 
formation of polyplex NPs core-stabilized by electrostatic (PEG-DMAEMA) or a combination of 
electrostatic and hydrophobic interactions PEG-(DMAEAM-co-BMA).  The data in Figure 2 
suggest that polymers with 60 mole % BMA or less in the poly(DMAEMA-co-BMA) block exist in 
a unimeric state at pH 5.2, and as a result, this pH was used for formulation of siRNA-loaded 
polyplex NPs in subsequent studies.  
 
 
Fig. 5.3 Formulation of siRNA polyplex NPs at pH 5.2. A) siRNA packaging efficiency was dependent 
on both polymer composition and N:P ratio.  B) Gel images used to quantify siRNA packaging efficiency 
(concatenated image containing 6 gels, each of which was internally controlled for quantification purposes).  
 
Assembly and Characterization of siRNA-loaded Polyplex NPs 
The polymers were mixed with siRNA at pH 5.2 to trigger polyplex NP formation, and it 
was found that the N:P ratio required to fully complex siRNA was proportional to the % BMA in 
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the polymer. Agarose gel electrophoretic mobility shifts were used to calculate the % siRNA 
packaging efficiency achieved using different formulation conditions (Fig. 5.3).  However, even 
polymers 40B and 50B were able to efficiently package siRNA at an N:P of 10 or greater. In 
contrast, the 75B polymers were found to encapsulate only 38% of the siRNA even at an N:P of 
20.  The polyplex NPs formed from all polymers at N:P of 10:1 had hydrodynamic diameter of 
~100 nm and approximately neutral zeta potential (Appendix Fig. A14). It was also found that 
reduction of the pH to 4.0 enabled efficient siRNA complexation of 50B at a lower charge ratio of 
5:1, further supporting the importance of pH in siRNA packaging efficiency of these formulations 
(Appendix Fig. A15). 
 
Cellular Uptake, Gene Silencing, and Cytotoxicity 
Flow cytometry revealed that 0B polyplexes had the highest uptake and transfected nearly 
100% of cells. 50B polyplex NPs were internalized significantly more than 40B or 60B (Fig. 5.4A). 
Despite the higher relative uptake of 0B (p<0.05), 50B polyplexes produced significantly greater 
luciferase silencing (94% reduction in the protein level at 48h when compared to scrambled 
control siRNA) relative to all other polymers in MDA-MB-231 breast cancer cells transduced to 
constitutively express luciferase (Fig. 5.4B, p<0.05). Though the benchmark formulation (0B) 
produced the greatest uptake, it produced only 20% luciferase silencing. The increased gene 
silencing activity of 50B NPs suggests that they are more efficient in navigating intracellular 
delivery barriers (i.e., increased cytoplasmic release) relative to 0B polyplexes. Treatment with 
the polyplex NPs was also shown to be non-toxic to MDA-MB-231 cells (not shown) and NIH3T3 
fibroblasts at the concentrations used in gene silencing experiments (Fig. 5.4C). The complete 
data set is listed in Appendix Fig. A18-S20. 
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Fig. 5.4 50B-based polyplex NPs have the optimal combination of siRNA uptake, gene silencing 
bioactivity, and cytocompatibility in vitro. A) Flow cytometry measurement of transfection efficiency and 
B) bioluminescence measurement of luciferase knockdown in vitro; NT=no treatment, LF=Lipofectamine 
2000, SCR=50B polyplexes loaded with scrambled siRNA. C) There was no cytotoxicity of any of the 
formulations at the concentrations tested.  Statistical significance was evaluated by ANOVA at a confidence 
level of p<0.05 and all groups were found to be significantly different except for the paired groups marked 
with *,†, or NS. 
 
 
Fig. 5.5 Polyplexes formulated with 50B show active endosome disruption and escape. A-C) 
Hemolysis was both pH and composition dependent, with 50B siRNA polyplexes showing the most 
desirable pH-dependent membrane disruption behavior; 50B polyplexes did not disrupt erythrocyte 
membranes at pH 7.4, but produced robust hemolysis at pH 6.8, which is representative of early 
endosomes. All polyplexes were made at N:P of 10:1, and hemolysis was measured at A) 1 µg/mL, B) 5 
µg/mL and C) 40 µg/mL polymer. D-E) Confocal images showing colocalization of the endosome/lysosome 
dye Lysotracker® with the cy5-labeled dsDNA cargo. Colocalization graphs are shown as insets. F) 50B 
polyplexes showed decreased % colocalization of dsDNA cargo with lysosomes relative to 
Lipofectamine2000 (* signifies p<0.01). 
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Endo-lysosomal Escape 
A major intracellular delivery barrier of siRNA nanocarriers is endosomal entrapment and 
trafficking for lysosomal degradation or exocytosis [252].  The current polymer family was 
designed to form polyplex NPs that destabilize at endo-lysosomal pHs, exposing the membrane 
disruptive poly(DMAEMA-co-BMA) polymer block. As a screen for active endosomal escape 
behavior, the pH-dependent membrane disruptive activity of siRNA-loaded polyplex NPs was 
measured using a red blood cell hemolysis assay [293]. At all N:P ratios tested, polyplexes made 
with 40B, 50B, and 60B generated switch-like, pH-dependent membrane disruption. Percent 
hemolysis of each polymer increased as the polymer concentration was increased and as the 
buffer pH was decreased. The pH where the hemolytic transition occurred mirrored the trend seen 
for destabilization of polymer NPs (Fig. 5.2) and was inversely dependent on the %BMA content 
in the poly(DMAEMA-co-BMA) block (Fig. 5.5A-C).  Polyplex NPs made with the 50B polymer 
had optimal pH-responsive behavior based on producing membrane disruption in a pH 
environment representative of early and late endosomes but not at physiologic pH. Furthermore, 
the pH-dependent membrane disruptive behavior of 50B was similar between the polymer-only 
micelle and polyplex NP forms (Appendix Fig. A16).  This suggests that presence of the anionic 
siRNA did not inhibit pH-dependent particle destabilization and exposure of the membrane 
disruptive poly(BMA-co-DMAEMA) block of polyplex NPs exposed to acidic pH. Although they did 
not fully disassemble like the polymer-only micelles (Fig. 5.2), the polyplex NP hydrodynamic 
diameter increased upon exposure to buffers of decreasing pH, suggesting that swelling and/or 
reorganization of the polyplex structure leads to exposure of the core-forming block under these 
conditions (Appendix Fig. A17).   
To assess intracellular trafficking and endo-lysosomal escape, confocal microscopy was 
used to measure colocalization with the fluorescent dye Lysotracker®. Diffuse staining of the cy5-
labeled dsDNA cargo was visualized in cells incubated with 50B polyplexes for 24h (Fig. 5.5D), 
and 50B polyplex delivery resulted in significantly lower Lysotracker® colocalization relative to 
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Lipofectamine (colocalization appears yellow, Fig. 5.5E). The colocalization was further 
visualized by plotting color values of non-background image pixels in a dot plot where colocalized 
signal falls on the y=x line, free siRNA falls on the y-axis, and lysosomes not containing siRNA 
fall on the x-axis (inset graphs). These combined data quantitatively and qualitatively suggest that 
polyplexes are able to efficiently overcome intracellular endo-lysosomal delivery barriers.  This 
outcome is in agreement with the results from the pH-dependent hemolysis experiment, which 
suggests that 50B polyplexes are finely tuned to disrupt membranes in pH values representative 
of the endo-lysosomal pathway.  These combined results suggest that 50B polyplexes improve 
the intracellular bioavailability of internalized siRNA, and this may mechanistically account for 50B 
having the highest gene silencing bioactivity of the polymers screened in vitro (Fig. 5.4B). 
 
Polyplex Stability and Hemocompatibility  
For intravenous siRNA delivery systems, avoidance of destabilization and/or nonspecific 
interactions with cells and other blood components is key to general hemocompatibility and for 
maximizing blood circulation time in order to allow for passive tumor accumulation or active tissue 
targeting of intact, bioactive NPs. Nanoparticle PEGylation improves these properties,[294] and 
we hypothesized that optimization of the polyplex core could be an avenue to further enhance 
stability. Polyplex NPs made with 40B, 50B, and 60B were stable and did not aggregate or 
dissociate over a period of 24 h in PBS as assessed with DLS (Appendix Fig. A21).  Förster 
Energy Resonance Transfer (FRET) was used as another measure of stability where 50B-NPs 
were co-loaded with FAM- and cy5- labeled dsDNA. FRET emission of the acceptor dye is only 
observed when the two fluorophores are co-encapsulated in the core of the NPs.[295] FRET-NPs 
made with 50B also retained an equivalent %FRET after 48 hours of storage at room temperature, 
further indicating that siRNA remains stably encapsulated in the core of the polyplexes (Appendix 
Fig. A21).  
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Ex vivo experiments in human whole blood were done to measure nonspecific red blood cell 
interactions and stability of polyplexes. After a 1 hour incubation in whole blood, polyplex NPs 
made with 50B were 74% retained in the serum fraction, whereas commercial standards PEI (5%) 
and Lipofectamine 2000 (48%) were more significantly associated with the cellular fraction 
following centrifugation (Fig. 5.6A). As a measure of whole blood stability, FRET-NPs were 
incubated for 1 hour in whole blood, and measurement of the FRET signal in the serum fraction 
showed that the 50B polyplex NPs retained a high %FRET signal of 77% while Lipofectamine 
2000 showed a significant (p<0.05) decrease in relative %FRET to 35% of the baseline signal 
(Fig. 5.6B).  
Rapid urine excretion of many intravenously-delivered cationic siRNA polyplexes occurs 
due to dissociation in the kidney glomerular basement membrane (GBM), which has high 
composition of the anionic macromolecule heparan sulfate [123, 296]. To model this phenomenon 
in vitro, we incubated FRET-NPs with heparinized saline (2 U/mL) and measured stability over 
time.  This experiment showed that destabilization was dependent on the composition of the core-
forming polymer block, indicating that 40-60% BMA resulted in significantly greater stability 
(p<0.05) compared to 0B and 25B polyplex NPs (Fig. 5.6C). Higher concentrations of heparin 
(>10 U/mL) were capable of dissociating the higher %BMA polyplexes 40B-60B (Appendix Fig. 
A22). These data suggest that incorporation of hydrophobic content will slow the rate of kidney 
filtration of siRNA-loaded polyplex NPs.  
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Fig. 5.6 50B polyplex NPs demonstrate enhanced stability upon exposure to heparin and human 
whole blood and have a longer circulation half-life and improved tissue biodistribution in vivo. A) 
When incubated in blood at 37°C, a significant fraction of the PEGylated polyplexes remained in the serum, 
indicating that they nonspecifically interact with erythrocytes to a significantly lesser degree than PEI 
(p<0.05). B) FRET-NP incubation in diluted human whole blood suggested that all PEGylated polyplex NPs 
were significantly more serum stable than the commercial standard Lipofectamine 2000 (p<0.05). Statistical 
significance for A-B was evaluated by ANOVA at a confidence level of p<0.05 where all groups were found 
to be significant except for those designated with †. C) Stability of FRET-NPs incubated in 2 U/mL of heparin 
was enhanced for polyplexes with 40-60% BMA content in the core-forming polymer block. D) The 
circulation half-life was 18.4 min for 50B and 5.8 min for 0B (p<0.05, n=3). E) When measured intravitally, 
systemic biodistribution was significantly higher (p<0.05) for the 50B injected mice. F) Intravital imaging of 
intravenously injected 50B and 0B polyplex NPs reveals rapid kidney distribution and systemic clearance 
of 0B. G) Representative time course images are shown noting significantly more overall systemic 
biodistribution of fluorescent siRNA delivered via 50B polyplexes relative to the more rapidly cleared 0B 
polyplexes. H) Imaging of siRNA fluorescence in kidneys excised at 5 minutes post injection confirmed 
increased, rapid renal filtration of siRNA delivered via 0B polyplex NPs relative to the 50B group. I) 
Postmortem tissue biodistribution showed preferential accumulation in liver and kidneys, with significantly 
decreased systemic clearance of 50B vs 0B at 20 min, 1 hr, and 2 hrs post-injection (p<0.05, n=3). J) 
Measurement of cumulative fluorescence in all of the organs at 2hr post injection showed significantly 
increased biodistribution and retention in the organs for 50B relative to 0B polyplex NPs  (p<0.05). K) 
Representative tissue biodistribution images are shown from 2h. Statistical significance for in vivo 
experiments was evaluated with ANOVA at a confidence level of p<0.05, and * designates significance.  
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Circulation half-life and biodistribution  
Increased resistance to heparin-mediated destabilization of 50B-based polyplex NPs was 
found to be functionally significant in vivo and yielded a 3.2-fold increase in the blood circulation 
half-life (18.4 ± 0.53 vs. 5.80 ± 0.58 minutes) and 3.4-fold increase in area under the curve (AUC) 
(14.0mg*h/L vs. 4.1 mg*h/L) relative to the benchmark polymer 0B (p<0.05 for both half-life and 
AUC, Fig. 5.6D). The blood circulation half-life of 0B was consistent with previous studies on 
PEGylated polycationic siRNA carriers, which have typically shown values <5 min and is 
associated with rapid decomplexation and systemic removal in the kidney [123, 296]. Our 
combined data suggest that increased hydrophobicity in the core of polyplexes made with 50B 
polymers increased NP stability in the presence of heparin, slows renal clearance in vivo, and 
increases blood circulation time. These data suggest 50B will biodistribute more efficiently to other 
tissues and will be potentially targeted more efficiently to tumors or other pathological sites.  
To this end, tissue biodistribution of 0B and 50B siRNA polplex NPs were examined 
intravitally immediately following injection and at postmortem endpoints of 5 min, 20 min, 1 hr, 
and 2 hr post-injection. In agreement with the 50B polyplexes having less rapid renal 
decomplexation and siRNA removal through the urine acutely following injection, there was an 
immediate spike in concentration of siRNA in the kidneys of 0B polyplex-treated mice, and overall 
systemic clearance of siRNA was faster than following delivery with 50B polyplexes (Fig. 5.6E-
F). This trend is shown visually in representative mice (Fig. 5.6G), and the full panel of intravital 
images is shown in Appendix Fig. A23. Imaging of kidneys excised from mice that were 
euthanized 5 minutes post-injection confirmed the intravital imaging data and showed a 2.2-fold 
increase in siRNA distribution in the kidney for 0B relative to 50B (Fig. 5.6H). Liver biodistribution 
was noted at 5 min, 20 min, 1 hr and 2 hr endpoints for 0B and 50B NPs and suggested that 
uptake in the liver is the primary route for removal of intact NPs (Fig. 5.6I-K). There was 
significantly greater quantity of siRNA in the liver and kidneys for 50B than 0B (p<0.05) at 20 min, 
1 hr, and 2 hrs.  Because 50B is partially susceptible to heparin decomplexation, the kidneys also 
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have higher fluorescence at the later time points based on continued clearance of the longer-
circulating 50B formulations.  The integrated fluorescence across all organs was 1.5 fold higher 
in 50B polyplexes than 0B after 2h (p<0.05, Fig. 5.6J), which is also consistent with slower 
removal through the urine and better overall biodistribution of 50B relative to 0B polyplexes.  
Importantly, we saw little uptake in the lungs and heart that would be associated with acute 
pulmonary toxicity that occurs with ineffectively-shielded cationic polyplexes [139]. 
The combined data from Fig. 5.6 suggest that both polyplex surface PEGylation and 
incorporation of hydrophobic content in the core are beneficial for enhancing circulation half-life. 
PEG shielding improves circulation by decreasing aggregation with or adsorption to blood 
components, but does not fully shield the polyplex core from interaction with competing anions 
prevalent in the kidneys. The optimal combination of core hydrophobicity and PEG shielding 
achieved with 50B polyplexes increased the circulation half-life and is anticipated to improve 
passive tumor accumulation or, through functionalization with targeting ligands, retention in other 
target tissues. Poorer stability of 0B resulted in decreased systemic biodistribution due to rapid 
decomplexation and removal through renal filtration. This agrees with previous literature 
suggesting that siRNA delivered via simple polycations are substantially excreted through the 
urine within 1 min post-delivery [123, 296]. 
 
PPIB gene silencing in vivo 
The last objective was to confirm that 50B polyplex NPs remained bioactive in vivo. The 
liver, kidneys, and spleen were selected as target tissues based on their known reticuloendothelial 
system (RES) function and the results of the biodistribution analysis. An siRNA targeting the 
model/housekeeping gene PPIB was delivered because of the consistent expression level of 
PPIB, and knockdown was analyzed in tissues extracted 48 hours after intravenous injection. As 
shown in Fig. 5.7, 50B polyplex NPs robustly silenced PPIB in the liver by ~74% following an 
intravenous dose of 2 mg/kg siRNA. Furthermore, 50B generated significantly greater gene 
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silencing than 0B polyplexes injected at the 
same dose of 2mg/kg (p<0.05). Similarly, 50B 
polyplexes significantly silenced PPIB in the 
kidneys and spleen relative to scrambled 
controls (p<0.05), and 50B silencing was 
significantly greater in the spleen relative to 
0B (p<0.05, for 0B versus 50B in the kidney). 
Improved in vivo gene silencing by 50B 
polyplexes relative to 0B is consistent with 
their active, pH-dependent membrane 
disruptive function and increased in vitro 
bioactivity, stability, circulation time, and 
overall tissue biodistribution. The similar level 
of gene silencing measured in the different 
organs also implies widespread tissue distribution of intact, bioactive 50B polyplex NPs and that 
these NPs may be used to preferentially accumulate in a variety of target tissues if implemented 
with the appropriate targeting ligand. Importantly, all polyplex injections were well-tolerated by the 
mice, and no elevation in serum markers of liver toxicity ALT or AST were detected in mice treated 
with 50B or 0B at days 2 or 8 post-injection (Appendix Fig. A25). 
 
5.3 Conclusions 
We have synthesized and screened a small library of PEG-(DMAEMA-co-BMA) polymers for 
formulation of in vivo-ready siRNA nanocarriers designed to overcome key delivery barriers in the 
systemic circulation and inside target cells. PEG was used in the corona to impart hemo-
compatibilty and stability, and the combination of surface PEGylation and titration of hydrophobic 
content into the polyplex core resulted in better stabilized polyplexes with longer blood circulation 
Fig 5.7 In vivo gene silencing following 
intravenous delivery of 50B polyplex NPs. 
Gene silencing of the model gene PPIB was 
evaluated by PCR 48h after intravenous injection 
of 2 mg/kg siRNA doses. Significant differences 
were noted in the liver, kidney, and spleen 
between 50B and SCR groups (p<0.05) and in the 
liver and spleen between 50B and 0B (p<0.05). 
Markers of statistical differences: #,* - Liver; % - 
Kidney; &,$ - Spleen. 
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times. The 50B polymer had optimally-balanced cationic and hydrophobic content in the core-
forming block and formed polyplex NPs with improved resistance against destabilization in the 
kidneys in vivo and pH-dependent membrane disruptive activity ideally tuned for endosomal 
escape.  This resulted in slower renal clearance, increased circulation time, improved tissue 
biodistribution, and more potent gene silencing bioactivity in vivo.  The 50B siRNA polyplex 
nanoparticles provide a promising platform for future applications involving EPR-driven delivery 
to tumors in vivo or active receptor-ligand targeting to increase accumulation and uptake in 
specific cells or tissues. 
 
5.4 Materials and Methods 
Materials  
All materials were obtained from Sigma-Aldrich and used as received unless otherwise 
noted. An alumna column was utilized to remove inhibitors from DMAEMA and BMA monomers, 
and final purification of polymers was done with PD10 desalting columns (GE Healthcare, 
Waukesha WI). 
 
Synthesis of 4-cyano-4-(ethylsulfanylthiocarbonyl) sulfanylpentanoic acid (ECT) and PEG-ECT 
 The RAFT chain transfer agent (CTA) ECT was synthesized as previously described 
[132], and the R-group of the CTA was subsequently conjugated to PEG [297]. Briefly, 
dicyclohexylcarbodimide (DCC, 4mmol, 0.82g) was added to the stirring solution of mono 
methoxy-poly(ethylene glycol) (Mn = 5000, 2 mmol, 10g), ECT (4mmol, 1.045g), and DMAP 
(10mg) in 50 mL of dichloromethane.  The reaction mixture was stirred for 48h.  The precipitated 
cyclohexyl urea was removed by filtration and dichloromethanane layer was concentrated and 
precipitated into diethyl ether twice.  The precipitated PEG-ECT was washed three times with 
diethyl ether and dried under vacuum (Yield ~10g). 1H NMR (400 MHz CDCL3) revealed 91% 
substitution of the PEG (Appendix Fig. A11).  
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Polymer Synthesis and Characterization  
Reversible addition fragmentation chain transfer (RAFT) polymerization was used to 
synthesize a library of copolymers using the PEG-ECT macro-CTA. In all cases, the degree of 
polymerization (DP) was 150, and the monomer plus CTA was 40% wt/vol in dioxane.  The 
polymerization reaction was carried out at 70°C for 24 h using AIBN as the initiator with a 5:1 
[CTA]:[Initiator] molar ratio.  A series of polymerizations were carried out with monomer feed ratios 
of 0:100, 25:75, 40:60, 50:50, 60:40, and 75:25 mol% [BMA]:[DMAEMA]. The reaction was 
stopped by exposing the polymerization solution to air, and the resulting diblock polymers were 
precipitated into an excess of pentane.  The isolated polymers were vacuum dried, re-dissolved 
in water, further purified using PD10 columns, and lyophilized. Polymers were characterized for 
composition and molecular weight by 1H nuclear magnetic resonance spectroscopy (NMR, Bruker 
400Mhz Spectrometer equipped with 9.4 Tesla Oxford magnet).  Absolute molecular weight of 
the polymers was determined using DMF mobile phase gel permeation chromatography (GPC, 
Agilent Technologies, Santa Clara, CA, USA) with inline Agilent refractive index and Wyatt 
miniDAWN TREOS light scattering detectors (Wyatt Technology Corp., Santa Barabara, CA). All 
results are shown in Appendix Fig. A12 and A13.   
 
Characterization of pH-dependent Polymer Micelle Assembly and Disassembly in the Absence of 
siRNA 
Each lyophilized polymer was dissolved in 100% ethanol, and aliquots of this solution were 
mixed with an 8-fold excess of phosphate buffer at pHs 7.4, 7.1, 6.8, 6.2, 5.6, and 5.2 or citrate 
buffers of 4.6, and 4.0 to make a 1 mg/mL stock solution.  Each stock solution was diluted an 
additional 10-fold into phosphate or citrate buffer of the same pH to form 100 µg/mL polymer 
stocks, and the pH-dependence of self-assembly of each polymer into NPs was assessed using 
dynamic light scattering (DLS, Malvern Zetasizer Nano ZS, Malvern UK).  For imaging by 
 82 
transmission electron microscopy (TEM), carbon film-backed copper grids (Electron Microscopy 
Sciences, Hatfield, PA) were inverted onto droplets containing aqueous NP suspensions (1 
mg/mL) and blotted dry.  Next, samples were inverted onto a droplet of 3% uranyl acetate, allowed 
to counterstain for 2 min, and again blotted dry.  Finally, samples were desiccated in vacuo for 2 
h prior to imaging on a Philips CM20 system operating at 200 kV (Philips, EO, Netherlands).  
 
Assembly and Characterization of siRNA-loaded Polyplex NPs  
Polyplex NPs loaded with siRNA were made by mixing pH 4.0 stock solutions of polymer 
and siRNA at N:P ratios of 5, 7, 10, or 20.  The final charge ratio was calculated as the molar ratio 
of cationic amines on the DMAEMA (50% are assumed to be protonated at physiologic pH) to the 
anionic phosphates on the siRNA.  After mixing, these solutions were diluted 5-fold to 100 µL with 
phosphate buffer to adjust the final pH to 7.4.  After mixing, samples were incubated for 30 
minutes, and 15 ng siRNA for each sample was loaded onto a 4% agarose gel containing ethidium 
bromide to assess siRNA packaging efficiency. The gels were run at 100 volts for 35 minutes and 
imaged with a UV transilluminator.  Quantification was conducted using ImageJ version 1.45s 
(Freeware, NIH, Bethesda, MD).  Hydrodynamic diameter and zeta potential of the resulting 
polyplex NPs were measured using a Malvern Zetasizer Nano ZS.   
 
Cell Culture  
Human epithelial breast cancer cells (MDA-MB-231) were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Gibco Cell Culture, Carlsbad, CA) supplemented with 10% Fetal Bovine 
Serum (FBS, Gibco), and 0.1% gentamicin (Gibco).  Mouse Embryonic Fibroblasts (NIH3T3) were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco Cell Culture, Carlsbad, CA) 
supplemented with 10% Bovine Calf Serum (BCS, Gibco), and 1% penicillin-streptomycin (Gibco). 
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Flow Cytometry Assessment of siRNA Intracellular Delivery  
MDA-MB-231 breast cancer cells were seeded in 24-well plates at a density of 40,000 
cells/cm2 and allowed to adhere overnight. The cells were treated with polyplexes loaded with 
Alexa488-labeled DNA (21mer duplexes mimicking siRNA molecules) at a final concentration in 
each well of 100 nM in media supplemented with 10% FBS.  After the designated treatment time, 
cells were washed with PBS and trypsinized.  Cells were centrifuged and resuspended in PBS 
containing trypan blue to quench extracellular fluorescence.  Relative cell fluorescence was 
quantified via flow cytometry to measure NP intracellular delivery (FACSCalibur, BD Biosciences, 
Franklin Lakes, NJ). 
 
Cytotoxicity 
Cytotoxicity of siRNA-loaded polyplex NPs was determined by measuring relative cell 
number based on luciferase activity.  NIH3T3s were transduced with a lentivirus to constitutively 
express luciferase (LR-3T3s), and it was confirmed that cell number was directly proportional to 
luciferase signal (Appendix C) [298].  LR-3T3s were seeded in black-walled 96-well plates at a 
density of 12,500 cells/cm2 and allowed to adhere overnight. Next, cells were treated with fresh 
polyplexes at concentrations of 50, 100, and 200 nM siRNA/well (100 μL volume, n=5 for each 
treatment). After incubation for 24 h, the cells were given fresh luciferin-containing media (150 
µg/mL).  Bioluminescence was quantified using an IVIS Imaging System 200 series (Xenogen).   
 
In Vitro Gene Silencing 
MDA-MB-231 breast cancer cells were transduced with a lentivirus to constitutively 
express luciferase (L231, Appendix C). L231 cells were seeded in black, clear bottom 96 well 
plates at a density of 12,500 cells/cm2 and allowed to adhere overnight.  Next, cells were treated 
for 24 h with polyplex NPs containing anti-luciferase siRNA (Ambion) in 10% FBS media. Media 
was then replaced with luciferin-containing media (150 µg/mL), and bioluminescence was 
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measured using an IVIS 200 Series imaging system (Xenogen).  Next, cells were incubated for 
an additional 24 h in slow growth media (DMEM supplemented with 1% FBS, and 0.1% 
gentamicin), and bioluminescence was subsequently re-measured.  Bioluminescence data was 
normalized to total protein content in cell lysates which was measured via the Bradford assay 
(Bio-Rad). 
 
Hemolysis Assay  
Whole blood was extracted from anonymous, consenting human donors and red blood 
cells (RBCs) were isolated according to well established protocols.[293] RBCs were then 
incubated with the free polymers or with siRNA-loaded polyplex NPs (concentrations ranging 1 - 
40 µg/mL) in buffers of 7.4, 6.8, 6.2, and 5.6, which model the environments in the extracellular 
space and in the more acidic vesicles of the endo-lysosomal pathway.  After 1 h of incubation, 
the RBCs were centrifuged and the supernatant was spectrophotometrically analyzed at 451 nm 
in order to determine percent hemolysis relative to Triton X-100 detergent.  
 
Confocal Microscopy Imaging of Endo-lysosomal Escape  
MDA-MB-231 cells were seeded at a density of 12,500 cells/cm2 in 8-well chamber slides 
(Nunc – Thermo Fisher Scientific Inc., Waltham, MA). The cells were treated with cy5-labeled 
dsDNA loaded polyplex NPs at 100 nM or Lipofectamine 2000 according to manufacturer’s 
specifications. After treatment, media was replaced with Lysotracker® (Invitrogen Life 
Technologies, Grand Island, NY) containing media (75 nM), and cells were incubated for 1 h 
before imaging with confocal microscopy (Zeiss LSM 710Meta, Oberkochen, Germany) equipped 
with differential interference contrast (DIC). Images were analyzed using ImageJ with a 
colocalization extension JaCOP previously described [299]. 
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Analysis of Polyplex Stability and Hemocompatibility 
NPs were loaded with Fӧrster Resonance Energy Transfer (FRET, using FAM and Cy5) 
pair-labeled 23mer dsDNAs (a model for siRNA) (FRET-NPs).  Fluorescent intensity was 
measured using a spectrophotofluorometer with an excitation wavelength of 488nm (Jobin 
Yvon/Horiba Fluorolog-3 FL3-111, Horiba Scientific, Kyoto Japan).  FAM emission was collected 
at 520nm ± 3nm, and Cy5 emission was obtained at 670nm ± 3nm.  %FRET was calculated as a 
ratio of the fluorescent intensity as follows: 
Eqn. 5.1 %𝐹𝑅𝐸𝑇 =
𝐼670
𝐼520+𝐼670
 
For serum stability measurements, FRET-NPs were added into human whole blood diluted 
1:3 in PBS at 100 nM (50 nM for each DNA).  Treated blood samples were loaded into a black, 
round bottom 96 well plate and placed on a shaker for 5 minutes before incubating at 37oC for 1 
h.  Plates were then centrifuged at 500 x g for 5 minutes, and then 50 µL of supernatant (diluted 
blood serum) from each well was transferred into a black, clear bottom 96 well plate.  
Fluorescence was measured using a Microplate Reader and %FRET was calculated using Eqn 
1. In parallel experiments to assess hemocompatibility ex vivo, polyplex NPs loaded with FAM-
labeled dsDNA were used to quantify the percent of NPs in the supernatant, as a measure of 
inertness, or ability to reduce nonspecific adsorption to or aggregation with RBCs. 
Because siRNA decomplexation by heparan sulfate-containing glomerular basement 
membrane (GBM) in the kidney is a primary cause for rapid systemic clearance of polycation-
siRNA nanoparticles [123, 296], the stability of FRET-NPs was measured in the presence of 2 
U/mL of heparin sodium salt in DPBS. The fluorescence emission was measured over time using 
a microplate reader with an excitation wavelength of 488 nm and an emission wavelength of 670 
nm (Tecan Infinite F500, Männedorf, Switzerland).  
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Biodistribution 
Balb/c mice (6-8 weeks of age) were injected intravenously into the tail vein with polyplex 
NPs containing a dsDNA (model for siRNA) labeled with 5' IRDye® 800CW (Integrated DNA 
Technologies, IDT). Blood samples were collected at 2, 5, 10, 15, and 20 minutes (maximum 2 
blood collections per mouse).  Separate cohorts of mice were euthanized for additional blood 
sample collection and organ harvesting for biodistribution analysis at 5min, 20 min, 1 hour, and 2 
hours post-injection. Blood was centrifuged at 500xg for 5 minutes and the supernatant was 
measured for fluorescence using a plate reader (Tecan) with 790 nm excitation and 810 nm 
emission.  In addition, mice were monitored intravitally using an IVIS 200 for the first 20 minutes 
post-injection in order to measure the kinetics of biodistrubition to the liver and kidneys. The backs 
of mice were shaved the day before injection and imaged with the dorsal side facing the camera 
to visualize and measure kidney and liver biodistribution. Regions of interest (ROIs) were drawn 
around the liver, kidneys, and the entire mouse to measure organ-specific and total fluorescence, 
respectively. An IVIS 200 was used to quantify the biodistribution in the explanted lungs, heart, 
liver, kidney, and spleen using Living ImageTM 4.3 quantification software.  
 
In Vivo PPIB Silencing  
Balb/c mice (6-8 weeks of age) were injected intravenously into the tail vein with polyplex 
NPs containing a dicer-substrate siRNA designed against cyclophilin B (PPIB, IDT) at a dose of 
2 mg/kg.  Mice were sacrificed at 48h, and the RNA was extracted from organs with TRIZOL 
(Invitrogen, Carlsbad, CA) and purified with RNEasy spin column (Qiagen, Venlo, Netherlands).  
The expression of PPIB was evaluated by RT-PCR using the ΔΔCt method normalizing to 
GAPDH.   
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Statistical Methods  
All measurements are presented as mean ± standard error of the mean. ANOVA was used 
to determine statistical significance, and p<0.05 was considered significant.  
 
Ethics Statement  
The animal studies were conducted with adherence to the guidelines for the care and use 
of laboratory animals of the National Institutes of Health (NIH). All experiments with animals were 
approved by Vanderbilt University’s Institutional Animal Care and Use Committee (IACUC). 
Human whole blood was collected from anonymous donors in accordance with an approved 
Institutional Review Board (IRB) protocol. 
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Chapter 6 
Synopsis and Future Directions 
6.1 Summary 
 As biologists continue to elucidate the molecular mechanisms for disease, there is a 
growing need for engineered platforms to solve the drug delivery challenges associated with 
correcting and treating the diseased state. Biomacromolecular drug delivery stands to improve a 
host of diseases by reaching molecular targets previously considered ‘undruggable’. Of these 
biomacromolecules, small interfering RNA (siRNA) is of particular interest due to siRNA’s specific 
and potent post-transcriptional gene silencing. These studies set out to develop a platform for 
local siRNA delivery that solves the delivery challenges of siRNA in a safe and biocompatible 
manner and applied this platform for sustained silencing of the angiogenesis regulator prolyl 
hydroxylase domain protein 2 (PHD2) to improve tissue regeneration. 
 In Aim 1, the platform was developed from the ground up and tested in vitro. pH-
responsive endosomolytic nanoparticles (NPs) were synthesized through the controlled radical 
polymerization technique and used to condense siRNA into nanoparticles (si-NPs). These si-NPs 
were lyophilized and incorporated into a polyurethane (PUR) scaffold which permitted sustained 
release to the local environment. Importantly, this study showed that the si-NP-PUR platform 
released bioactive nanoparticles that were non-toxic. However, there was a loss in activity of the 
si-NPs when released from the scaffold. 
 In Aim 2, the bioactivity of the si-NPs was improved through the use of a non-reactive 
excipient trehalose. In addition, trehalose also provided a mechanism for tuning the release rate 
of si-NPs from the scaffold. These new formulations were tested in vivo for tunable and sustained 
release, biocompatibility, and gene silencing. Importantly, this study showed potent gene silencing 
in mouse subcutaneous implants that was controllable based on the concentration of trehalose 
and sustained for 35 days. 
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 Aim 3 sought to apply this platform for the sustained silencing of a therapeutically relevant 
gene as a proof of principle and to demonstrate clinical translatability. In order to improve 
angiogenesis in the tissue engineered scaffold, prolyl hydroxylase domain protein 2 (PHD2) was 
sought as a negative regulator of the transcription factor hypoxia inducible factor 1α (HIF-1α). 
Previous studies had shown that stabilization of HIF-1α triggered a ‘growth-program’ resulting in 
the up-regulation of pro-angiogenic genes (e.g. VEGF and FGF-2) along with pro-healing genes 
(e.g. SDF-1) [217, 218, 300]. This study showed that through the sustained silencing of PHD2, 
pro-angiogenic genes were increased two-three fold resulting in a three-fold increase in vascular 
cross sectional area by IHC and a three-fold increase in vascular volume by microCT.  
 Finally, Aim 4 applied this platform to the sustained silencing of PHD2 in full thickness 
excisional wounds in streptozotocin (STZ) induced diabetic rats. This study is described in more 
detail in Appendix D. Though gene silencing was not witnessed at the later time points (day 7 and 
day 14), PHD2 treated rat wounds showed a significant increase in vascular area by histology 
(Appendix Fig. A28). Both the PHD2 treated and SCR treated groups re-epithelialized in 2 weeks 
showing no apparent difference in wound healing capcity. Future work will address the limitations 
of this study and apply new materials to improve the gene silencing (section 6.4).   
 An important aspect of siRNA delivery exists in intravenous delivery and it was considered 
an important problem to pursue in addition to the aims above. Chapter 5 detailed the development 
of a modified nanoparticle optimized for IV delivery that improves pharmacokinetics of siRNA. 
Importantly, PEG-shielded, hydrophobically stabilized nanoparticles improved circulation time 3.2 
fold compared to previously published PEG-DMAEMA resulting in significant gene silencing in the 
liver, kidneys, and spleen. 
 Together, these studies show that synthetic biomaterials may be used to address the 
delivery barriers of siRNA resulting in delivery platforms that can be modified and adapted for a 
wide range of pathologies.  
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6.2 Concerns and Limitations 
 Though the platforms developed in these studies were tested for toxicity and 
biocompatibility, it is important to note the following concerns related to nucleic acid delivery. The 
innate immune recognition of siRNA and the pathological response to cationic nanomaterials are 
two major hurdles that materials scientist and biologists are addressing and overcoming to allow 
clinical translation of gene silencing. Both of the following hurdles can be addressed with thorough 
screening of target and control siRNAs and careful consideration of the side-effects of the chosen 
delivery system. 
 
Innate Immunity 
Technologies for intracellular delivery of siRNA have advanced rapidly and are potentially 
approaching widespread adoption for clinical use. However, it should be cautioned that 
intracellular delivery of siRNA can lead to recognition by toll-like receptors (TLRs).  TLRs 
recognize molecular patterns that are associated with pathogens including double stranded RNA, 
which can be representative of the viral genome.  TLR response could result in pathological 
symptoms clinically, and it has also led to the false interpretation of pre-clinical results in studies 
related to viral repression, oncology, angiogenesis, and inflammation [55]. As a result of this 
phenomenon, it is recommended that siRNA studies carefully look for potential TLR-mediated 
effects.  It is also advisable to replicate studies with multiple siRNA sequences against the gene 
of interest in order to ensure that any phenotypic changes are solely attributable to silencing of 
the target gene. Importantly, there is also ongoing work to create siRNAs that avoid immune 
activation entirely, and we are optimistic that these nonspecific effects will become more 
completely understood and entirely avoidable. For example, it is thought that immune recognition 
is sequence dependent [56] and that carefully selected siRNA sequences may avoid activation of 
the immune system.  Also, chemical modifications of siRNA with 2-OMe nucleotides can help to 
eliminate TLR activation while producing negligible effects on gene silencing efficacy [55]. In our 
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work, we examined potential TLR responses by measuring TNFα and STAT-1 mRNA levels and 
found no large increase indicative of TLR recognition (Appendix Fig. A10) [301].    
 
Inflammatory Response to Cationic Materials 
 The nanoparticles developed in these studies were designed to improve cytocompatibility 
over off-the-shelf lipid transfection reagents or polycationic materials such as PEI (Appendix Fig. 
A5). Many of the recently developed materials for delivering siRNA into the cytoplasm of cells 
employ cationic surface charge to electrostatically condense and entrap siRNA. A large body of 
research has shown that these cationic materials may alter gene expression independent of the 
siRNA that is being targeted [302] which may result in incorrect interpretation of data including 
falsely interpreting negative results or clouding positive results.  
 Applying cationic delivery materials for siRNA-mediated wound healing may create a 
deleterious side-effect on tissue regeneration by increasing inflammatory signaling that is desired 
to be repressed.  This was witnessed when comparing scrambled siRNA loaded into cationic 
nanoparticles inside polyurethanes with a decrease noted in blood vessel formation (Appendix 
Fig. A26A-B).  Also, bone marrow derived macrophages treated with nanoparticles with a 
scrambled siRNA showed a significant increase in TNFα levels indicating polarization of the 
macrophages toward and M1 phenotype (Appendix Fig. A26C). In this work, we have still shown 
a significant increase in blood vessel formation when PHD2 siRNA was used relative to NT and 
no apparent increase in toxicity. We noted a slight non-significant increases in TNFα levels in 
mouse subcutaneous implants when treated with a non-targeted, scrambled siRNA sequence 
(Appendix Fig A10) indicating the inflammation from the delivery platform we have selected is 
manageable and can be overcome with selected siRNA. In section 6.4, a brief discussion on 
possible future work to more effectively delivery siRNA without the cationic materials is provided. 
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6.3 Broader Impacts 
Ongoing work discussed in section 6.4 will apply this material to larger animal models for 
ischemic and chronic wound healing. Successful tests may generate industrial interest in applying 
the platform for clinical translation. While it is expected that this platform will be a strong candidate 
for clinical development, it is possible that clinical translation of this specific platform may not 
occur.  However, the impact of this technology is not limited to the clinic as this material is a 
powerful research tool for investigating loss of function for tissue engineering research.  
 
Therapeutic for Chronic Wound Healing 
 The platform developed in this work may generate interest in the medical device and 
pharmaceutical industry as a novel method for local gene silencing.  Gene silencing is beginning 
to generate industry interest with an increasing number of clinical trials showing promise [28]. 
However, there are still no clinically approved siRNA therapies, with only one clinically approved 
gene therapy [303] as the RNAi industry slowly recovers from an initial reluctance by the 
pharmaceutical industry. The cost associated with bringing a combination drug/device is 
astronomical approaching $700 million to $1.3 billion, according to the Tufts Center for the Study 
of Drug Development. To justify clinical development, the potential market must be large enough 
to support the product. Currently, the market for chronic wound healing is large ($25B) and is 
rapidly increasing due to the increasing prevalence in comorbidities. In fact, bioactive wound 
healing has an estimated market size of ~$1B and is considered one of the fastest growing 
segments of advanced wound care. The morbidity and mortality associated with non-healing 
wounds is also high including amputations and sepsis so products that reduce the clinical burden 
will be highly desired. Based on the cost analysis provided in Appendix D, the potential product 
would be competitive with other bioactive wound healing technologies. Acquisition by companies 
looking to expand their role in bioactive wound healing is a likely exit strategy (See Smith & 
Nephew’s recent acquisition of Healthpoint Biotherapeutics). 
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Tissue Engineering Research Tool 
 An additional impact that this platform may have is by creating a large body of knowledge 
by silencing genes locally and observing the effects on tissue regeneration, wound healing, or 
other biologic fates. This will decrease the cost and time loss accompanying creating mouse 
knockout models for tissue regeneration studies and allow only local silencing for more diverse 
genes. This platform may also be used for cell studies as a 3D tissue engineered construct as the 
polyurethane promotes cell ingrowth and division in vitro.  
 
6.4 Future Work 
 Based on the challenges laid out in 6.2 there is a wealth of future research that may be 
investigated including (1) improved siRNA chemistry to eliminate the need for an additional 
transfection material and (2) improving scaffold material such that the degradation rate matches 
the cell infiltration rate [163]. As described in Appendix D.2, the diabetic rat excisional wound 
healed rapidly in control groups, so a more chronic wound model may be pursued. As this platform 
is refined and improved, it will become important to test the materials in animal models for 
ischemic/chronic wound healing more representative of human skin. The porcine ischemic model 
may be a good model of human skin wounds that are pre-disposed to ulceration [304]. Another 
ongoing work will be the characterization of other silenced genes that may benefit regenerative 
medicine. An added benefit of this platform is that if PHD2 is deemed ineffective at promoting 
wound healing in diabetes, other siRNAs may be replaced with only minor screening 
requirements.  
 
6.5 Conclusion 
 With the increasing knowledge of the molecular mechanisms of disease and rapid 
advancements in materials science, RNAi is poised to become a high impact therapeutic much in 
the way mono-clonal antibodies have developed in the last two decades.  Coupled with an 
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increasing prevalence of chronic wounds, technologies that harness bioactive molecules to target 
the molecular basis of disease stand to greatly benefit quality of life.  
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A.1. Polymer Synthesis and Characterization 
 
Figure A1:  RAFT kinetics study on polymerization of pDMAEMA mCTA. A) Conversion is initially linear 
and then begins to plateau.  B) The log plot of the kinetics shows a linear first order polymerization kinetics.  
Eight hour polymerization time was selected for the desired block length and %conversion. 
 
 
Figure A2: Refractive Index traces from Gel Permeation Chromatography for macro CTA of DMAEMA 
(dotted line) and diblock copolymer (solid line)  
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Figure A3: 1H NMR in CDCL3 (A) and D2O (B) demonstrates micelle formation.  A)  CDCL3 spectrum has 
all peaks due to the good solvation of both blocks.  B) Peaks in the hydrophobic block are suppressed due 
to the poor solvation.  Peaks in the DMAEMA block show up the strongest. 
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Figure A4: si-NPs effectively complex siRNA and are serum stable.  Gel electrophoresis of si-NPs 
formulated at varying charge ratios shown in yellow letters.  The left half of the gel is in nuclease free water.  
The right half is completed in 50% Bovine Calf Serum proving stability to serum proteins.  A charge ratio of 
4:1 was utilized for further experimentation. 
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A.2. NP Cytotoxicity Measurement 
 
Figure A5:  Cytotoxicity profile of treatment groups shows minimal toxicity at the charge ratios used 
during this study.  
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B.1 siRNA and primer sequences  
Nucleic Acids were purchased from Integrated DNA Technologies (IDT, Coralville, IA, USA) 
based on the design principle that dsRNAs that contain a 27-mer antisense strand and a 25-mer 
sense strand have up to a 10-fold increased potency compared to 21-mer siRNA counterparts[1]. 
In addition, 2’-O-methyl (2-OMe) nucleotides were incorporated to improve duplex stability and 
nuclease resistance without affecting silencing activity or producing toxicity [2]. Minimal 2-OMe 
modifications on the backbone of the dsRNA were made to eliminate toll-like receptor  activation 
and an immune response, with negligible effects on the potency of gene silencing [3, 4]. All listed 
siRNAs were screened in vitro before use in vivo (Table A1). Fluorescent labels were used in 
portions of the manuscript including 6-FAM and cy5. These labels were obtained from IDT which 
are purified by HPLC. 
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Table A1 – Nucleic acid sequences 
Name Sequence mRNA 
Target 
Location 
Silencing 
(in vitro 
50nM) 
Reference 
dsDNA  S: 5’-FAM-GTCAGAAATAGAAACTGGTCATC-3’ 
AS:5’-GATGACCAGTTTCTATTTCTGAC-3’ 
N/A N/A [5] 
PPIB#1 
NM_011149 
S: 5’-GCCUUAGCUACAGGAGAGAAAGG[dA][dT]-3’ 
AS:5’-AUCCUUUCUCUCCUGUAGCUAAGGCUA-3’ 
329 10% N/A 
PPIB#2 
NM_011149 
S: 5’-GCAUGGAUGUGGUACGGAAGGUG[dG][dA]-3’ 
AS:5’-UCCACCUUCCGUACCACAUCCAUGCCC-3’ 
621 95% N/A 
PPIB#3 
NM_011149 
S: 5’-CGAUAAGAAGAAGGGACCUAAAG[dT][dC]-3’ 
AS:5’-GACUUUAGGUCCCUUCUUCUUAUCGUU-3’ 
199 30% N/A 
Anti-
Luciferase 
pGL2 
 
S: 5’-CGUACGCGGAAUACUUCGAAAUG[dT][dC]-3’ 
AS:5’-GACAUUUCGAAGUAUUCCGCGUACGUG-3’ 
230 55% [6, 7]  
Scrambled DS Scrambled Neg – from IDT N/A N/A  
PHD2 #1 S: 5’-ACAUAGUUACAAGAGGAAACAAGCC – 3’ 
AS: 5’-GGCUUGUUUCCUCUUGUAACUAUGUUG – 3’ 
2094 78%  
PHD2 #2 S: 5’-ACCUAACAGUAGAUGGUUGCCACTG – 3’ 
AS: 5’-CAGUGGCAACCAUCUACUGUUAGGUCG – 3’ 
2053 67%  
PHD2 #3 S: 5’ – GGUACGCAAUAACUGUUUGGUAUTT -3’ 
AS: 5’-AAAUACCAAACAGUUAUUGCGUACCUU – 3’ 
1278 8.2%  
     
PPIB 
Primers 
FWD: 5’-TTCCATCGTGTCATCAAG-3’ 
REV: 5’-GAAGAACTGTGAGCCATT-3’ 
   
GAPDH 
Primers 
FWD: 5’-CTCACTCAAGATTGTCAGCAATG-3’ 
REV: 5’-GAGGGAGATGCTCAGTGTTGG-3’ 
   
STAT-1 
Primers 
FWD: 5’-GCAACTGGCATATAACTT-3’ 
REV: 5’-GTGACATCCTTGAGATTC-3’ 
 
 
  
TNFα 
Primers 
FWD: 5’-CAAAGGGATGAGAAGTTC-3’ 
REV: 5’-TGAGAAGATGATCTGAGT-3’ 
 
 
  
PHD2 
Primers 
FWD: 5’-ATCTAACAGGTGAGAAAGGT-3’ 
REV: 5’-ACAGAAGGCAACTGAGAG-3’ 
   
VEGF 
Primers 
FWD: 5'-CCTGGTGGACATCTTCCAGGAGTA-3' 
REV: 5'-CTCACCGCCTTGGCTTGTCACA-3'   
 
   
FGF-2 
Primers 
FWD:  5'-CTCCAGTTGGTATGTGGCACT-3'  
REV: 5'-CAGTATGGCCTTCTGTCCAGG-3'  
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B.2. Poly[DMAEMA71-b-(BMA103-co-PAA68-co-DMAEMA57)]and nanoparticle (NP) 
characterization 
 
Figure A6: Characterization of Poly[DMAEMA71-b-(BMA103-co-PAA68-co-DMAEMA57)] and self-
assembled nanoparticles. These data are representative of the polymer and the NPs used in this study. 
The formulations are similar to those characterized in previous publications [8-10].  A) H1 NMR of the 
polymer was used to determine percent composition of each monomer. B) GPC for the DMAEMA 
macroCTA and the diblock copolymer were utilized to determine molecular weight and polydispersity. C) 
TEM of the NPs after micellar assembly of poly[DMAEMA71-b-(BMA103-co-PAA68-co-DMAEMA57)] shows a 
uniform structure of the particles(Scale = 100 nm). D) Flow cytometry of NIH3T3 mouse fibroblast uptake 
of fluorescently labeled dsDNA loaded into si-NPs and Lipofectamine 2000 relative to control cells with no 
treatment demonstrate a higher level of uptake for NPs. E) The hemolysis assay was used to demonstrate 
that the pH-dependent membrane disruptive activity of the NPs is appropriately tuned for endosomlytic 
behavior. F) All NP formulations used in this study were cytocompatible compared to a no treatment (NT) 
control, siRNA only (SI), and HiPerFect (HP) as shown by this LDH assay (note that 4:1 charge ratio 
(NH3+/PO4-) was utilized for all si-NPs formulations in these studies). 
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B.3. The Weibull model for release kinetics 
Equation A.1:    
𝑀𝑡
𝑀∞
= 1 − 𝑒𝑥𝑝(−𝑎 ∙ 𝑡𝑏) 
The Weibull model describes the % of mass of si-NPs released (Mt/M∞) at time t, where a is a 
constant based on the system, and b is a constant based on the release kinetics. Previous reports 
suggest that values of b < 0.75 indicate that Fickian diffusion is the dominant release mechanism 
[11, 12]. 
 
Table A2. Weibull Model Analysis – In Vitro Release Data 
Formulation a b R2 
LTI – 0T 0.0273 0.5511 0.992 
LTI – 1.25T 0.1582 0.3488 0.9183 
LTI – 2.5T 0.4797 0.3648 0.869 
LTI – 5T 1.729 0.4448 0.8736 
HDIT – 0T 0.026 0.336 0.9792 
HDIT – 1.25T 0.0399 0.3828 0.9764 
HDIT – 2.5T 0.0691 0.4818 0.9689 
HDIT – 5T 0.1451 0.4402 0.99 
 
 
Table A3. Weibull Model Analysis – In Vivo Release Data 
Formulation a b R2 
LTI – 0T 0.433 0.3052 0.8912 
LTI – 1.25T 0.9976 0.1599 0.8236 
LTI – 5T 1.336 0.2436 0.7426 
HDIT – 0T 0.2912 0.3707 0.8921 
HDIT – 1.25T 0.4716 0.3591 0.9295 
HDIT – 5T 0.867 0.317 0.8564 
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B.4. Representative release kinetics images 
 
Figure A7. Visual Representation of Release Kinetics. The release kinetics data (Figure 2K, 2L) was 
calculated by loading the si-NPs with Cy5-labeled siRNA and measuring the change in fluorescence within 
the PEUR scaffolds with intravital imaging.  In each case, a region of interest (shown in red) was defined 
that contained just the scaffold, and the average fluorescence was calculated and compared to the initial 
image of PUR before implantation (after compensating for loss of fluorescence from imaging through the 
tissue). The representative images above visually demonstrate the rate of loss of Cy5 fluorescence within 
the scaffold.  
 
 
B.5. The 4 parameter logistic model used for IC50 and dose response analysis 
 
Equation A.2:                            %Expression =
−1
(1+(
𝑥
𝐼𝐶50
)
𝑏
)
+1 
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B.6. Temporal control of the gene silencing profile for scaffolds composed of HDIT PEUR 
 
Figure A8: PCR for PPIB expression in the HDIt scaffolds using the same method described for the LTI 
data shown in Figure 3C.  The temporal gene silencing profile was similar to that seen with the LTI based 
scaffolds.  
  
 122 
B.7. Infiltration of PUR scaffolds. Effect of formulation 
 
Figure A9: Microscopic view of Hematoxylin and eosin (H&E) stained sections shows the morphology and 
the degree of infiltration at day 21 and day 35 in LTI and HDIt based scaffolds demonstrating similar levels 
of cellular infiltration.  Scale bar = 200 um. (n=1) 
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B.8. PCR for TNFα and STAT-1 markers of inflammation and TLR activation 
 
Figure A10: PCR for STAT-1 and TNFα normalized to GAPDH expression indicates that the delivery 
platform does not activate nonspecific inflammation or TLRs. A statistically insignificant increase in the 
scaffolds loaded with si-NPs containing scrambled siRNA may indicate a small non-specific inflammatory 
response to either the scrambled siRNA or the polymer, but is not indicative of the orders of magnitude 
increase in STAT-1 produced by TLR activation [13].  In the scaffolds containing si-NPs loaded with PPIB 
siRNA (PPIB-NP), there was a significant decrease in both STAT-1 and TNFα, suggesting anti-
inflammatory activity was produced by silencing the model gene PPIB. This aligns with the known functions 
of PPIB as a pro-inflammatory secretory product of macrophages [14] that is increased in response to 
inflammatory stimuli [15] and that plays a role in adhesion of T-lymphocytes [16]. It has also been previously 
identified that inhibition of CD147 and PPIB interactions is a viable therapeutic strategy for reduction in 
inflammation [17]. Although it is outside the scope of the current report, this result indicates that potent 
PPIB silencing has the potential to be used as an anti-inflammatory therapy. 
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B.9. Supplemental methods 
NP characterization 
The diblock copolymer used in this study is from the same synthesis previously reported [10]. The 
polymers were characterized by gel permeation chromatography (GPC, Shimadzu Corp., Kyoto, 
Japan) in DMF with 0.1 M LiBr using an inline Wyatt miniDAWN TREOS light scattering detector 
(Wyatt Technology Corp., Santa Barabara, CA) and H1  NMR (Bruker 400 MHz Spectrometer 
equipped with a 9.4 T Oxford magnet) for molecular weight and composition. Transmission 
Electron Microscopy (TEM, Philips CM20 Transmission Electron Microscope, EO, Netherlands) 
was used to evaluate micelle diameter and morphology. A gel retardation assay was used to 
select the charge ratio (NH3+/PO4-), and 4:1 was used for all experiments. Flow cytometry was 
performed on NIH3T3 fibroblasts treated with a concentration of 50nM FAM labeled dsDNA 
(Supplemental Table 1) and measured with a BD FACSCalibur flow cytometer (San Jose, CA).  
The data was analyzed using FlowJo software (version 7.6.4 Ashland, OR).  A pH-dependent 
hemolysis assay was performed using a standardized protocol [18] to characterize pH-dependent 
membrane disruption of the polymer at concentrations of 40 µg/mL, 5µg/mL, and 1µg/mL in 
buffers of pHs 7.4, 6.8, 6.2, and 5.8. The percent hemolysis was calculated using data collected 
using a plate reader (Infinite F500, Tecan Group Ltd., Mannedorf, Switzerland) to measure 
absorbance at 541 nm. Cellular toxicity was analyzed at a concentration of 50nM siRNA with 
varying charge ratios up to N:P of 8:1 using an LDH cytotoxicity kit (Roche, Basal, Switzerland). 
 
Western blot 
Frozen samples were extracted with UDC buffer (8 M urea, 10 mM dithiothreitol (DTT), 4% 
CHAPS containing Phosphatase I and II protease inhibitor cocktail (Sigma, St. Louis, MO)) 
by vortexing at room temperature overnight and centrifugation at 14,000 rpm for 15 min at 
4°C.  Soluble protein concentrations were determined using the Bradford assay (Pierce Chemical, 
Rockfort, IL).  Equal amounts (30 μg) of proteins were added to Laemmli sample buffer (Bio-Rad 
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laboratories, Inc. Hercules, CA), heated for 5 min at 100°C, and separated on 12% SDS 
polyacrylamide gels.  Proteins from the gels were transferred onto nitrocellulose membranes (Li-
COR Biosciences, Lincoln, NE) and blocked with blocking buffer for 1 hour at room 
temperature(Li-COR Biosciences, Lincoln, NE) prior to incubation overnight at 4°C with  antisera 
against PPIB (1:2000,Sigma) and ß-actin (1:250,Santa Cruz Biotechnology). Membranes were 
washed three times with TBS containing Tween 20 (0.1%) (TBST) and incubated with 680 nm 
and 800 nm infrared-labeled secondary antibodies (Li-Cor, Lincoln, NE) for 1h at room 
temperature.  The membranes were subsequently washed with TBST, and protein-antibody 
complexes were visualized and quantified using the Odyssey direct infrared fluorescence imaging 
system (Li-Cor Biosciences NE). 
 
Cardiac Perfusion and microCT 
Mice were sacrificed by CO2 inhalation and perfused with normal PBS containing 4 mg/mL 
papaverine hydrochloride (Sigma) and 100 U/mL Heparin followed by 10% neutral buffered 
formalin, followed by PBS with papaverine hydrodhloride and Heparin. Next, 30 mL of the lead 
chromate based contrast agent Microfil® (Flowtec) was injected into the left ventricle and allowed 
to cure overnight at 4°C.  Implants were retrieved and scanned using a microCT (uCT 50, Scanco 
Medical AG, Brüttisellen Switzerland) for vessel morphology, vascular volume and vascular 
thickness. Regions of Interest were selected by each slice selecting area inside the scaffold. 
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C.1 Supplemental Methods 
 
Luciferase Cell Line Derivation 
Mouse Embryonic Fibroblasts (NIH3T3, ATC) or Human epithelial breast cancer cells (MDA-MB-
231, ATCC) were plated into a 24 well plate and transfected with Lentiviral Expression particles 
for firefly luciferase, Red Fluorescent Protein (RFP), Blasticidin resistance, and a Bsd promoter 
(GenTarget Inc, San Diego, CA) at a multiplicity of infection (MOI) of 10. The cells were then 
incubated for 72 h, changing the media every 24 h, and monitored for RFP with fluorescent 
microscopy. Cells were trypsinized and transferred into 75 cm2 flasks and treated with blasticidin 
(10 ug/mL, based on predetermined kill curves).The luciferase signal and the cell number are 
linearly related in the range tested such that the cell line may be used to determine cell number 
longitudinally. See Supplemental Information from [19]. 
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C.2 siRNA Sequences 
 
siRNAs were purchased from integrated DNA technologies (IDT, Coralivlle, IA, USA). 27-mer 
antisense strand and 25-mer sense strand were used due to the increase potency relative to 21-
mer siRNAs[1].  Also, 2’-O-methyl (2-OMe) -modified nucleotides were used to improve stability, 
increase nuclease resistance, and eliminate toll-like receptor activation, with negligible effects 
on the level of gene silencing [2-4]. 
 
Table A4 – siRNA sequences 
Name Sequence Reference 
Scrambled S:  5’ – CGUUAAUCGCGUAUAAUACGCGUAT – 3’ 
AS: 5’ – AUACGCGUAUUAUACGCGAUUAACGAC – 3’ 
IDT 
PPIB S:  5’-GCAUGGAUGUGGUACGGAAGGUGGA – 3’ 
AS: 5’- UCCACCUUCCGUACCACAUCCAUGCCC – 3’ 
[20] 
dsDNA S:  5’-Fl-GTCAGAAATAGAAACTGGTCATC-3’ 
AS: 5’-GATGACCAGTTTCTATTTCTGAC-3’ 
Where Fl = FAM, cy5, IRDye800, or Alexa488 
[5] 
Luciferase Proprietary by Supplier Ambion 
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C.3 PEG-ECT Conjugation  
 
  
 
Figure A11 - Integration of the δ 1.88 s (CCNCH3) ECT peak and the δ 3.65s (-OCH2CH2-) PEG peak 
reveals the %conjugation as shown in Eqn. 1. This batch of PEG-ECT was used in all of the 
polymerizations. 
 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 𝐴. 3               %𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑖𝑜𝑛 =
∫ 1.88𝑠
3𝑝𝑟𝑜𝑡𝑜𝑛
∫(3.65𝑠)
4𝑝𝑟𝑜𝑡𝑜𝑛 ∙ 113𝑟𝑒𝑝𝑒𝑎𝑡𝑠
=⁄ 91.2% 
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C.4 NMR of polymer panel 
 
Figure A12 – NMR of polymer panel – continued on next page 
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Figure A12 – NMR of polymer panel. Polymers were analyzed by 1H NMR (400 MHz, CDCl3) which were 
used to quantify molecular weight by integrating the δ 3.65s (-OCH2CH2-) PEG peak and comparing to 
the δ 2.58s (-CH2NH2) of the DMAEMA, the δ 4.05s(-O-CH2CH2-) of the DMAEMA and the δ 3.95s(-O-
CH2CH2-)  of the  BMA. This method could also be used to quantify %composition by comparing the 
molar content of DMAEMA monomers and BMA monomers. The results are listed in Table 1 in the 
manuscript.  
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C.5 GPC of Polymer Panel 
 
Figure A13 – Molecular weight and polydispersity obtained by GPC – GPC using DMF with 0.1M LiBr as 
the mobile phase was used to analyze the molecular weight and polydispersity of the synthesized polymers.  
Molecular weights were quantified with an inline light scattering (dotted lines) and refractive index (solid 
lines) detectors using calculated dn/dc values determined offline. All results are listed in Table 1 in the 
manuscript. 
 
0
0.2
0.4
0.6
0.8
1
10 15 20 25 30
R
e
la
ti
v
e
 I
n
te
n
s
it
y
Elution Volume (mL)
PEG-ECT RI
PEG-ECT LS
0B RI
0B LS
0
0.2
0.4
0.6
0.8
1
10 15 20 25 30
R
e
la
ti
v
e
 I
n
te
n
s
it
y
Elution Volume (mL)
PEG-ECT RI
PEG-ECT LS
25B RI
25B LS
0
0.2
0.4
0.6
0.8
1
10 15 20 25 30
R
e
la
ti
v
e
 I
n
te
n
s
it
y
Elution Volume (mL)
PEG-ECT RI
PEG-ECT LS
40B RI
40B LS
0
0.2
0.4
0.6
0.8
1
10 15 20 25 30
R
e
la
ti
v
e
 I
n
te
n
s
it
y
Elution Volume (mL)
PEG-ECT RI
PEG-ECT LS
50B RI
50B LS
0
0.2
0.4
0.6
0.8
1
10 15 20 25 30
R
e
la
ti
v
e
 I
n
te
n
s
it
y
Elution Volume (mL)
PEG-ECT RI
PEG-ECT LS
60B RI
60B LS
0
0.2
0.4
0.6
0.8
1
10 15 20 25 30
R
e
la
ti
v
e
 I
n
te
n
s
it
y
Elution Volume (mL)
PEG-ECT RI
PEG-ECT LS
75B RI
75B LS
 133 
C.6 Extended DLS and Zeta Potential Characterization 
 
Figure A14 – DLS for each polymer-siRNA polyplex at a charge ratio of 10:1. Polyplexes are relatively 
monodispersed and centered around ~100 nm. Zeta potential measurements for 40B and 50B were -1.05 
±6.1 mV and -0.9 ±6.6 mV respectively.  
 
 
Figure A15 – Formulation of polyplexes at pH 4.0 improved siRNA encapsulation as shown in the gel for 
50B. When quantified 82%, 88%, 93% and 97% are complexed by 2:1, 5:1, 10:1, and 20: 1 respectively.  
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C.7 pH Dependence of Polymers and Polyplexes 
 
Figure A16 –RBCs incubated with polymer alone show a similar level of lysis as the data reported in the 
manuscript.  This provides strong evidence that at the charge ratio used (NH3/PO4 = 10/1) the addition of 
siRNA does not significantly alter the pH dependent lysis.  
 
 
Figure A17 –pH dependent DLS of 50B polyplexes (NH3/PO4 = 10/1) indicates a pH responsive 
destabilization and which indicates a stability loss similar to that reported in Figure 2.  
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C.8 Comprehensive in vitro data 
 
Figure A18 – Flow cytometry demonstrates a strong dependence of the polymer chemistry on cellular 
uptake. As demonstrated above, 0B had the highest fluorescence of any of the polymer formulations. 50B 
delivered more than 40B or 60B. (n=3) 
 
 
Figure A19 – Luciferase protein level silencing - L231 cells treated with polyplexes show varying levels of 
gene silencing with 50B being the highest. Additional data presented here indicate a dose dependent 
decrease in luciferase readings.  
 
 
Figure A20 –The full panel of cytotoxicity measurements on LR3T3 cells indicate low levels of toxicity at 
all measured doses in the polymers 40B, 50B, and 60B at 24h (left panel) and 48h (right panel) 
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C.9 Micelle Stability 
 
Figure A21 – Polyplexes were evaluated for stability by incubating in PBS and measuring the size over 
48h. As Fig. S7 demonstrates, polyplexes were stable in PBS maintain a similar size and PDI over the 
time course measured.  In addition, FRET was measured at 48h revealing 88% retention of the FRET 
signal suggesting polyplexes retained the siRNA cargo in the core of the micelle over 48h. 
 
 
Figure A22 – Hydrophobic stabilized micelles are still susceptible to high concentrations of Heparin -
When treated at 10U heparin / mL, polyplexes formulated from 40B, 50B, and 60B were no longer stable 
over the 100 min time course as demonstrated by the decrease in FRET. Also note that during this 
experiment, 0B and 25B were instantly destabilized to ~0% remaining FRET.  
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C.10. Full Biodistribution Panel 
 
Figure A23 – Intravital imaging of intravenous administered polyplexes reveal renal clearance and 
pronounced liver uptake in mice.  0B mice showed a lower level of biodistribution to the tissue which 
suggests rapid renal clearance. 0B mice also had a high level of %biodistribution in the kidney. 50B 
polyplexes showed better biodistribution throughout the body with highest localization to the liver after 
~3min.  
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Figure A24 – An acute (5 minute) terminal study demonstrated rapid renal filtration of siRNA delivered via 
0B polyplexes relative to 50B polyplexes  
 
C.11 Liver Compatibility of Polyplexes 
 
Figure A25 – Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measurements 
indicated that levels were normal at both 2 days and 8 days post treatment with intravenously injected 0B 
and 50B polyplexes. This is a good indication that polyplexes were well tolerated by the liver where the 
majority of the injected dose distributes.  
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Appendix D - Supplementary Information for Chapter 6 
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D.1 NP Inflammatory Profile 
 
 
Figure A26 – PHD2 knockdown generates significant pro-angiogenic response, however, SPNs create a 
pro-inflammatory response that may inhibit angiogenesis. A) Quantification of vessel density by histology 
and µCT revealed a significant decrease in the PUR loaded with SCR-SPNs but an increase in vessel 
density in the PHD2-SPN group. B) Representative µCT and CD31 IHC. C) Primary mouse bone marrow 
derived macrophages increase TNFα production when exposed to SPNs. 
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D.2. Pro-Angiogenic Effects of PHD2 Silencing in Diabetic Rat Excisional Wounds 
 
Methods 
To investigate the PHD2 siRNA platform for improved wound healing, an excisional wound 
healing model that has been used extensively was adapted. Male 350-375g Sprague-Dawley rats 
were obtained and fasted overnight. Streptozotocin (STZ) was injected at 50mg/kg and 
hyperglycemia was monitored for 10 days (>300mg/dL). The wound site was shaved and full 
thickness excisional wounds were made in the dorsal skin. PUR with either no NPs (Empty), 
scrambled si-NPs (SCR), or PHD2 si-NPs (PHD2) were implanted in the wound bed and covered 
with NU-gel and Tegaderm. Ketoprofen was administered daily for 4 days. The rats were kept for 
7 and 14 days then sacrificed by CO2 inhalation and tissue was extracted and analyzed for gene 
expression changes by qRT-PCR and for vessel density by H&E. The same treatments were also 
examined using PTK-UR chemistry which has been shown to improve tissue regeneration by 
better matching the degradation rate with the cell infiltration rate [21]. 
 
Results and Discussion 
     We recently showed that PTK-UR scaffolds more effectively stented subcutaneous 
pockets in rats than PEUR materials [21]. This stenting behavior of PTK-URs was noted in the 
more mechanically challenging excisional rat wound model.  This stenting effects retains the open 
scaffold pore morphology and enhances the quantity and quality of granulation tissue formation 
within the wound site (Fig. A.27 A,C). Using H&E sections, this effect was quantified, and PTK-
UR scaffolds were both thicker and had a higher relative percentage of scaffold interior filled with 
granulation tissue relative to PEUR materials (Fig. A.27 B,C). 
At day 14, wound areas were evaluated for vascular density and it was found that loading 
of PEUR and PTK scaffolds with PHD2 si-NPs increased vascular density relative to their 
respective SCR controls by 1.6 fold and 1.8 fold respectively (Fig. A.28).  
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At these later time points (day 7 and day 14), there was no detectable level of gene 
silencing or increase in HIF-1α regulated genes (not shown). Due to the increased rate of scaffold 
infiltration and healing in the rat model compared to the mouse model, the silencing effect may 
disappear more rapidly. Future work will investigate an earlier time point and investigate tissue 
sections by immunohistochemistry for improvements in wound healing.  
 
 
Figure A27 – PTK-UR more effectively stent the wound area and promote tissue infiltration at day 7. A) 
Wound size is reported showing that PTK-UR more effectively stent the wound area (*p<0.05). B) PTK-UR 
more effectively promote tissue ingrowth than the PEUR (***p<0.005) 
 
 
 
Figure A28 – PHD2 knockdown in diabetic rat excisional wounds generates a significant increase in blood 
vessel area in polyester urethanes and polythioketal based polyurethanes at day 14. A) Representative 
macro and micro histology shows the excisional wound by H&E. B) Quantified histology slides reveal a 
significant increase in blood vessel area by treatment with PHD2 siRNA compared to scrambled 
siRNA.(p<0.05)   
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D.3. Broader Impact: Cost Analysis and Clinical Viability  
One of the biggest hindrance to siRNA therapy is the cost of RNA synthesis.  Currently, 1 
μmol of DsiRNA cost $981 from IDT (idtdna.com) which is roughly $1 per nmol.  We are currently 
using around 500pmol per animal or about 0.50c per implant.  If this technology were adapted for 
human use, the volume of the implant and thus the dose would increase.  The average chronic 
wound volume is about 35 cm3 [22] which would require ~$115 worth of DsiRNA.  Currently, a 
dosing regimen of Regranex® costs $586 [23] making this technology competitive with the price.  
The cost of DsiRNA of the same sequence will also decrease in bulk quantities, and the dose 
may be reduce by ½ or ¼ for therapy reducing the price more. Overall, this technology should be 
price competitive with competing biologic delivery technologies.  With the increase in medical 
costs, technologies should strive to decrease prices of medical care.  Technologies like these 
should decrease costly amputations and the subsequent human cost of a long-term disability by 
reducing the number of amputations and improving the quality of life for diabetic patients. 
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